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ABSTRACT
This thesis is divided into three parts
, united by the
theme of the development of selective inhibitors of
mammalian cell DNA polymerase delta (pol S). The first part
consists of an investigation of the cytotoxic mechanism(s)
of certain 2-substituted adenine analogs
, selected on the
basis of their inhibitory properties towards DNA polymerase
alpha (pol a) and mammalian cell DNA synthesis. The second
is a direct search for inhibitors of isolated pol S
, and an
investigation of inhibitory mechanisms. The third consists
of measurement of the effects of a selective pol S inhibitor
on cellular DNA synthesis.
Mechanism of Cytotoxicity of 2-substituted adenine
analoqs. The mechanism of inhibition by 2- (p-
butylanilino) -2' 
-deoxyadenosine (BUAdA), and related
compounds , of Chinese hamster ovary (CHO) cell (3H) thymidine
(( 3H) TdR) incorporation
, was investigated. The potency of
the compound could largely be explained by its potency (IC
= 23 M) as an inhibitor of CHO cell ( H)TdR uptake. BuAdA
inhibi ted incorporation by CHO cells of (32p) phosphate into
DNA relatively weakly, displaying an IC
so value of 80 
Differential inhibition of DNA polymerases alpha and
del ta. Known DNA polymerase inhibitors of a structurally
wide range were screened for their ability to inhibit pol 
derived from calf thymus selectively with respect to pol a
derived from the same tissue. Pyrophosphate (PPi) and
difluoromethanediphosphonate each inhibited pol S weakly,
but with greater potency than pol 
Based on this lead
, an
expanded series of PPi analogs was screened.
Carbonyldiphosphonate (COMDP) inhibited pol S with a potency
(Ki = 1. M) twenty-two times greater than that displayed
for pol a. Kinetic studies indicated that COMDP inhibited
pol S competitively with the dNTP specified by the template
but not competitively with the template: primer. Analogous
experiments with pol a showed that the compound inhibited
that enzyme uncompetitively with the dNTP
, and not
competitively with the template:primer.
COMDP was a weak
inhibitor of the 
3' S' exonuclease activity of pol S
displaying an ICSO value greater than 1 
ro.
Inhibition of permeabilized cell DNA synthesis bv a
selective pol S inhibitor. The potency of COMDP as an
inhibitor of permeabilized CHO cell DNA synthesis (ICSO =
200 ~M) did not clearly indicate the participation of pol 
in cellular DNA replication.
Prospectus. The thesis concludes with a prospectus for
the development of pol S inhibitors with improved properties
compared to COMDP.
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CHAPTER I
INTRODUCTION
A. Roles of the Mammalian Cell DNA PolYmerases
in DNA Repl ication
An understanding of mammalian cell DNA replication will
require an understanding of the properties and roles of the
enzymes which catalyze the key reactions in that process.
There are four known enzymes in mammalian cells capable of
catalyzing DNA pOlYmerization, DNA polymerases alpha (pol
a), beta (pol ), gamma (pol Y) and delta (pol S) (reviewed
in Fry & Loeb, 1986). The roles of the four DNA polymerases
in DNA replication and repair have not been precisely
determined, and that determination represents one of the
fundamental problems in modern biology.
DNA ol erases beta and amma robabl do not
contribute to enomic DNA re lication. The roles of pol 
and pol Y in mammalian cell DNA metabolism seem limited to
the repair of genomic DNA and metabolism of mitochondrial
DNA , respectively. Experiments employing the antibiotic
aphidicolin (Brundret et al. , 1972) (Figure IV-3) have
provided evidence against the hypothesis that pol 
, pol Y
or both participate in DNA replication. The compound is a
potent inhibitor of pol a (Ikegami et al., 1978) and pol 
(Lee et al., 1981; Goscin & Byrnes , 1982), and is without
effect on pol and pol Y (Ikegami et al., 1978). DNA
replication is highly sensitive to inhibition by aphidicolin
(Ikegami et al. , 1978; Hanaoka et al. , 1979; Berger et al.,
1979; Huberman et al., 1981), consistent with the hypothesis
that neither of the aphidicolin resistant DNA polymerases
participate in DNA replication. A second line of evidence
concerns the level of activity of the various DNA
polymerases as a function of the stage of the cell cycle.
One would expect that the activity of a replicative DNA
polymerase would increase prior to S phase. The level of
pol a activity positively correlates with the level of
replicative DNA synthesis throughout the cell cycle (see
below), but the levels of pol and pol Y are independent of
DNA replication (Chang et al. , 1973; Fry & Loeb , 1986).
addition, Zmudzka et ale (1988) showed that the cellular
level of pol mRA also was independent of the cell cycle.
Experiments using selective inhibitors of pol have
supported the idea that the mission of that enzyme is DNA
repair (Miller & Chinault , 1982a; 1982b; Cleaver , 1983;
Yamada et al., 1985), although the experiments are
complicated by, for example , the participation of pol a in
DNA repair , and the apparent abil i ty of pol a and pol 
compensate for one another in repair synthesis when the
other enzyme is selectively inhibited (Fry & Loeb , 1986).
Pol Y is found in mitochondria (Bolden et al., 1977), and is
likely the only DNA polymerase in mitochondria (Bolden et
al., 1977 Zimmerman et al. , 1980). It is bel ieved to be
the only DNA polymerase involved in mitochondrial DNA
metabolism (Fry & Loeb, 1986). Pol Y also has been
identified in nuclei (Bertazzoni et al.
, 1977 Hubscher et
al., 1977), although there is no positive evidence for a
role for that enzyme in genomic DNA metabolism (Fry & Loeb
1986) .
A role for DNA erase al ha in DNA re lication is
firml established. The most firmly established role for
any of the known mammalian DNA polymerases in DNA metabolism
is that of pol a in genomic DNA repl ication. Three major
lines of evidence , summarized below , indicate that pol a is
a major or the sole replicative DNA polymerase in mammalian
cells. (i) The level of pol a activity in cells closely
tracks the level of replicative DNA synthesis throughout the
cell cycle (Fry & Loeb , 1986). Pol a activity is low in
quiescent cells (Bertazzoni et al. , 1976), and increases
dramatically when cells are stimulated to divide (Chang et
al., 1973 Bertazzoni et al. , 1976) or when synchronized
cells enter S phase (Spadari & Weissbach, 1974 Chiu &
Baril , 1975). Wong et ale (1988) found that the level of
pol a mRNA is significantly higher in proliferating cells
than in quiescent cells. Wahl et ale (1988) showed that pol
mRA levels increased just prior to the peak of DNA
synthesis in quiescent cells stimulated to divide,
suggesting that regulation of pol a gene expression is at
the transcriptional level. Thommes et ale (1986)
demonstrated that the increase in pol a activity during S
phase was accompanied by an increase in the synthesis of the
enzyme. (ii) Inhibitors of pol a inhibit mammalian cell DNA
replication (Fry & Loeb, 1986). Ikegami et al. (1978) found
that aphidicolin prevented cell division in sea urchin
embryos as a result of its inhibition of DNA synthesis.
Pedrali-Noy et al. (1980) later showed that aphidicolin was
capable of synchronizing HeLa cells by blocking their entry
into S phase. Liu and Loeb (1984) isolated pol a from
aphidicolin resistant mammalian cells , and found that the
enzyme was aphidicolin resistant. Unfortunately, in vivo
studies with aphidicolin are ambiguous with respect to the
roles of pol a and pol 5 in DNA synthesis , because
aphidicolin inhibits the two enzymes with equal potencies
(Lee et al., 1981; Goscin & Byrnes, 1982). The possibility
that inhibition of DNA synthesis by aphidicolin is at least
found that DNA synthesis in permeable human fibroblasts
partially a result of inhibition of pol a in vivo
supported by the observations of Miller et al. (1985), who
could be inhibited up to 70 to 80% by the monoclonal
antibody SJK 132-20 (Tanaka et al. , 1982), a reagent which
neutralizes pol a but not pol 5 (Byrnes, 1985). (iii) 
mouse cell line which was temperature sensitive in DNA
replication yielded a temperature sensitive mutant form of
pol a (Murakami et al., 1985; Eki et al. , 1986; Eki et al.
1988) .
Role of DNA erase delta in DNA re lication.
Al though pol 5 has been known for about thirteen years
(Byrnes et al., 1976), there is no direct evidence for its
involvement in DNA replication. There are no known
condi tional mutants of pol Until recently, there were
neither any selective small molecule inhibitors of pol 
(Talanian et al. , submitted), nor any inhibitory monoclonal
antibodies specific for pol S (Lee et al., 1989). In the
absence of pol S-specific reagents , the function of pol 
has been inferred indirectly by assessment of the amount of
replicative DNA synthesis which is resistant to inhibition
by selective pol a inhibitors but sensitive to inhibition by
aphidicolin. Dresler and Frattini (1986; 1988) found that
2- (p-n-butylphenyl) -2' 
-deoxyguanosine 5' -triphosphate
(BuPdGTP, Figure I-I) (Wright & Dudycz, 1984), a potent
inhibitor of pol a (Khan et al., 1984) which inhibits pol 
only weakly (Byrnes, 1985; Lee et al., 1985), inhibited
replicative DNA synthesis in permeabilized human fibroblasts
with a potency several orders of magnitude less than that
which it displayed for inhibition of pol Dresler and
Frattini concluded that the unexpected resistance of DNA
synthesis to inhibition by BuPdGTP may have been a result of
the participation of a BuPdGTP-insensitive enzyme , possibly
pol 5, in DNA synthesis. Hammond et al. (1987) made
somewhat different observations, but came to the same
conclusion. They found that pol a-specific neutralizing
monoclonal antibodies or BuPdGTP inhibited replicative DNA
synthesis in permeable cells by roughly 50%, and that the
remaining activity was resistant to those inhibitors but
sensitive to inhibition by aphidicolin. The latter results
were consistent with the possibility that replicative DNA
synthesis was catalyzed in roughly equal proportions by pol
a and pol other, less direct studies have also supported
the hypothesis that pol 5 participates in DNA replication.
For example , Prelich et ale (1987a) have shown that the pol
5 cofactor proliferating cell nuclear antigen (PCNA) (see
below) is required for SV40 replication; to the extent that
SV40 replication is an accurate model for genomic DNA
replication, that observation implicates pol S in genomic
DNA replication. The observations of Hurwitz and coworkers
(Lee et al., 1988) have, however, put the latter conclusions
in doubt. They found that PCNA stimulates SV40 replication
by counteracting the effect of an inhibitory factor , rather
than by the direct stimulation of pol stronger evidence
for the involvement of PCNA, and thus by association pol 5
HN 
Figure 1-1.
II II 
-O- -O- -O.O. O. 
OH 4HN+(Etb
BuAdA TP
II II 
-O- -O- -O.0' O. 
OH 4HN+ (Et)3
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Structures of BuAdATP and BuPdGTP
in cellular DNA replication, is the observation of Liu et
al. (1989) that inhibition of Chinese Hamster Ovary (CHO)
cell PCNA biosynthesis, by means of introduction into cells
of an antisense 01 igonucleotide complementary to PCNA mRA
effectively blocked entry of CHO cells into S phase.
B. Properties of DNA polymerase Delta
DNA erase delta: a mammalian DNA 
erase with 
5' exonuclease activit Pol S was first isolated from
rabbit erythroid hyperplastic bone marrow (Byrnes et al.,
1976) . The enzYme has since been isolated from a variety of
sources, including calf thYmus (Lee et al., 1980), CV-1
cells (Hammond et al., 1987), human placenta (Lee & Toomey,
1987) and HeLa cells (Nishida et al., 1988), suggesting that
pol 5 is a ubiquitous mammalian DNA polYmerase. The major
feature of pol 5 which distinguished it most clearly from
the other known mammalian DNA polymerases was its possession
of a 3' ~ 5' exonuclease activity, which seemed to be on the
same peptide as the DNA polYmerase activity (Byrnes et al.,
1976; Goscin & Byrnes, 1982). Most replication specific
prokaryotic DNA polymerases have an associated 3' ~ 
exonuclease activity which increases the replication
fidelity of the DNA polymerase by a "proofreading" or
editing" mechanism (Goodman, 1988; Kunkel, 1988). wi th few
exceptions (Chen et al., 1979; ottiger & Hubscher, 1984;
Skarnes et al., 1986; Reyland et al. , 1988), experiments
indicate that pol a is devoid of a 3' ~ 5' exonuclease
activity, and the absence of that activity is believed to be
the reason for the relatively low replication fidelity of
pol a vitro (Loeb & Kunkel , 1982). It is believed that
if the low fidelity of pol a vitro is not an artefact
other mechanisms , including "accessory" nucleases , must
compensate in vivo for the low replication fidelity of pol a
vitro. In the case of pol 5 , replication fidelity is
increased significantly by the action of its associated 3' ~
5' exonuclease activity (Byrnes et al. , 1977; Kunkel et al.
1987; Sabatino & Bambara, 1988); behavior which strongly
supports the hypothesis that pol 5 is a replicative DNA
polymerase in vivo
Enz matic Pro erties of DNA ol erase delta com arison
with DNA erase al ha. Pol a and pol 5 also can b
distinguished on the basis of the requirements and behavior
of their DNA polymerase activities
, as well as the presence
of associated activities. Pol 5 prefers synthetic
template:primers such as poly(dA) :oligo(dT) and the
alternating copolymer poly (dA-dT) , although the pattern of
template preferences of that enzyme depends on its source
and the method of its purification (So & Downey, 1988). Pol
a prefers template:primers with a high primer density,
although, like pol S, the template preference of pol a is a
function of its method and source of purification (Kaguni &
Lehman, 1988). Pol a and pol S also can be distinguished by
their processivity; the number of nucleotides that, on
average, the enzyme adds to a growing primer chain before
the enzyme dissociates from the template: primer. Pol a is
generally regarded as a nonprocessive (distributive) enzyme
adding on the order of 5 to 100 nucleotides to a growing
primer chain before dissociation (Fry & Loeb, 1986). In the
presence of PCNA, the processivity of pol S is at least two
orders of magnitude greater than that generally reported for
pol a (Downey et al., 1988; So & Downey, 1988). In the
absence of PCNA, pol 5 synthesizes DNA in a distributive
manner (Tan et al., 1986; Prelich et al., 1987b) , although
processi ve forms of pol 5 in the absence of PCNA are known
(Focher et al., 1989; see below). The difference in the
observed processivities of pol a and pol vitro may not
reflect their processivities in vivo ; under the appropriate
conditions , which may or may not reflect in vivo conditions
highly processive synthesis by both enzymes is possible
(Sabatino et al., 1988). Another distinguishing
characteristic is that pol 5 is capable of strand-
displacement synthesis (Downey et al., 1988), whereas pol a
is not (Murakami et al., 1986; Downey et al., 1988).
Finally, pol a contains a tightly associated DNA primase
activity which catalyzes the synthesis of RNA primers
allowing the enzyme to use single stranded DNA as a template
(Fry & Loeb, 1986). with one possible exception (Crute et
al., 1986), pol 5 does not appear to conta in a DNA pr imase
activity.
PCNA: A stimulator cofactor of DNA ol erase delta.
PCNA is a cell cycle regulated nuclear protein whose rate of
synthesis closely tracks the rate of DNA synthesis in
proliferating cells throughout the cell cycle (for a review,
see Celis et al., 1987). PCNA is identical with a
previously described cell cycle regulated nuclear protein
called cyclin (Mathews et al., 1984). PCNA is an accessory
protein of pol 5 (Tan et al., 1986; Bravo et al., 1987;
Prelich et al., 1987b), capable of stimulating the activity
of that enzyme more than two orders of magnitude (Tan et
al., 1986), depending on the assay conditions. Tan et al.
(1986) and Prelich et al. (1987b) have observed that PCNA
stimulates pol 5 by increasing its activity and its
processivity. PCNA-dependent and PCNA insensitive forms of
pol 5 have been described (Crute et al., 1986; Focher et
al., 1988c; 1989): calf thymus has been the source of both
(Lee et al., 1984: Focher et al., 1989). The relationship
between PCNA-sensitive and insensitive forms of pol 5 is not
known. There are no known preparations of pol a which are
stimulated by PCNA.
structural relationshi between DNA erases al
and delta. During most of the history of pol S, the
structural relationship between it and pol a was unknown.
The hypothesis that pol S was a precursor to or breakdown
product of pol a, or perhaps a posttranslationally modified
form of pol a, seemed at least as likely as the hypothesis
that they were different gene products. Cotterill et ale
(1987) observed that separation of the polymerase subunit
from the four peptide Droso hila pol a-primase complex
revealed a 3' 5' exonuclease acti vi ty; later, the same
group observed (Reyland et al., 1988) that the isolated
polymerase subunit is, like pol 5, far less sensitive to
inhibi tion by BuPdGTP than the intact pol a-primase. The
latter observations supported the hypothesis that pol a and
pol 5 were somehow structurally related. However, recent
observations seem to have tilted the argument in favor of
the hypothesis that pol a and pol 5 are the products of
different genes. First, Lee and Toomey (1987) have shown by
Western blotting that a mouse heteroantiserum raised against
pol 5 reacted with pol S but not with pol a, and that
monoclonal antibodies raised against pol a displayed no
reactivity with pol The same group (Lee et al., 1989)
later showed that of eight pol 5-neutralizing monoclonal
antibodies , two were inhibitory to pol a, indicating that
the two proteins are distinct, but have some structurally
common relationship. The second and perhaps more important
observation was that of Focher et al. (1989), and Wong et
al. (1989) who independently showed by tryptic peptide
analysis that the DNA polymerase catalytic subunits of calf
thymus pol and pol 5 were different. The gene encoding
human pol a has been cloned and sequenced (Wong et al.,
1988); until the pol 5 gene also has been cloned and
sequenced, the structural relationship between the two
enzymes will remain unclear.
Differential inhibitors of DNA 
erases al ha and
delta . Pol and pol 5 display similar sensitivities to
aphidicolin (Lee et al., 1981; Goscin & Byrnes , 1982) and
sulfhydryl-reacting compounds such as N-ethylmaleimide
(Byrnes, 1984). For some time, those observations were
cited as evidence for the hypothesis that pol 5 was a form
of pol a. Khan et al. (1984) and Lee et al. (1985) showed
that BuPdGTP and its dATP analog, 2- (p-n-butyalanilino) -2'-
deoxyadenosine 5' -triphosphate (BuAdATP, Figure I-I)
displayed differential inhibition of pol a and pol 
inhibi ting the former enzyme with far greater potency than
the latter. Byrnes (1985) also showed that the pol a-
neutralizing antibody SJK 132-20 (Tanaka et al., 1982) had
no effect on pol 5 at concentrations which were completely
inhibitory to pol a. Differential inhibition of the two
enzymes reinforced the hypothesis that the two enzymes were
distinct gene products. Further, selective inhibition of
pol a by BuPdGTP and monoclonal antibodies facilitated
experiments designed to determine the role of pol 
independently of pol S, in DNA metabolism. Analogous
experiments designed to determine the role of pol S were not
possible, since all known differential inhibitors of the two
enzymes did so by selectively inhibiting pol 
C. Why Might There Be Two Replicative DNA Polymerases
in Mammalian Cells?
metr at the re lication fork. All known DNA
polymerases catalyze DNA synthesis by adding dNMP monomers
to a growing primer chain exclusively in the 5' ~ 
direction (Kornberg, 1980). As a result, there is a
fundamental aSYmetry at the replication fork, wherein the
"leading strand" is synthesized toward the replication fork
in a continuous manner, and the "lagging strand" is
synthesized away from the fork from a number of short RNA
primers in a discontinuous manner. The demands on a DNA
polymerase synthesizing leading and lagging strands at the
replication fork are therefore likely to be very different.
othesis: DNA ol erases al ha and delta catal 
and leadin strand s nthesis res ectivel Based
on the properties of pol a and pol 5, a model has been
proposed in which the two enzymes act coordinately at the
DNA replication fork, the former catalyzing lagging strand
synthesis , and the latter catalyzing leading strand
synthesis (Focher et al. , 1988a; Downey et al. , 1988).
continuous synthesis on the leading strand would best be
catalyzed by a highly processi ve enzyme such as pol S (see
above), while discontinuous synthesis might be catalyzed
most rapidly by the less processive pol Frequent primer
synthesis would be necessary during discontinuous synthesis
while continuous synthesis would require priming only
rarely. Thus , the presence of a primase activity tightly
associated with pol a and not with pol 5 (see above) makes
the former enzyme a more sui table candidate for lagging
strand synthesis than the latter. Finally, the ability to
conduct strand displacement synthesis
, a capability of pol 
but not of pol a (see above), might be crucial to the
function of a leading strand DNA polymerase
, since it may be
required to replicate through duplex regions of DNA
, whereas
a lagging strand polymerase would not. Focher et ale
(1988a) have observed that the ratio of pol a to pol 
activity in calf thymus was invariably 1: 1 using eight
different extraction procedures and in three subcellular
locations. Zhang and Lee (1987) observed that the ratio of
pol a to pol S activity in neonatal rat heart was constant
during maturation and terminal differentiation of heart
cells. Both sets of observations are consistent with the
hypothesis that pol a and pol 5 function as an aSYmetric
dimer.
The asymetric dimer hypothesis of Focher et al. (1988a)
and Downey et al. (1988) is not without precedent. It was
first proposed in 1980 (Sinha et al. , 1980) to explain the
properties of a reconstituted T4 bacteriophage DNA
replication system. The hypothesis has been supported by
the observations of McHenry (1982; 1988), who has described
the properties of a heterodimeric form of coli DNA
polymerase III. The two halves of the dimer differed
according to the identity of their associated subunits , and
had the functional properties expected of a leading and
lagging strand DNA polymerase.
D. Statement of the Problem
State of the art. As described above, a role for pol a
in mammalian cell DNA replication is firmly established, and
a role for pol 5 is not. However , considerable
circumstantial evidence suggests a role for pol 5 in DNA
replication , and a consideration of the properties of pol 
and pol a as well as the expected requirements of leading
and lagging strand DNA polymerases suggests a specific and
plausible model for the cooperation of the two enzymes in
DNA replication. The role of pol S in DNA repl ication, as
well as its structural and functional relationships with pol
, remain to be determined.
roach. At the start of the work described here,
discrepancies had been observed between the potencies of
several nucleoside and nucleobase analogs as inhibitors of
pol a and of mammalian cell DNA replication (see Chapter
III), suggesting that inhibition of pol a was an
insufficient model for inhibition of cellular DNA synthesis.
There also was considerable evidence, which has since been
supported, that pol a was probably not the only replicative
DNA polymerase. Both sets of observations suggested that
pol 5 might participate in mammalian cell DNA replication.
I approached the problem of the possible role of pol 
in DNA replication by seeking selective inhibitors of that
enzyme which might be used to probe its 
in vivo function.
began the search by investigating the cytotoxic mechanisms
of several compounds which appeared to inhibit cellular DNA
synthesis with unexpectedly great potencies relative to
their potencies as inhibitors of pol a and, thus , may have
acted on cells by potent inhibition of pol When I found
that the apparent potencies of these compounds as inhibitors
of cellular DNA synthesis was a function of the method
chosen for measuring cellular DNA synthe is, I took a
different approach, seeking directly an inhibitor of pol 
which was selective for that enzyme relative to pol 
I found such a compound, I thoroughly characterized its
When
action as an inhibitor of pol 5, and then measured its
effects on cellular DNA synthesis, in an attempt to detect
the participation of pol S in mammalian cell DNA
replication.
CHAPTER II
MATERIALS AND METHODS
A. Materials
3H)TdR, ( 3HJurd, (3HJLeu, ( 3HJdTTP, ( 3HJdGTP,
32p) phosphate, (32 pJ dGTP
, (
32pJ dCTP and (32 pJ dATP were
purchased from New England Nuclear or Amersham. Poly (dA) ,
poly(dC), oligo (dT) ((d)T12-18J, oligo(dG) ((d)G12-18J and
Sephadex G-2S were purchased from Pharmacia. Cal f thymus
DNA was purchased from Worthington. Except as noted, all
other materials were purchased from Sigma or VW.
B. Inhibitors
Melting points were determined on a Mel-temp apparatus
and are uncorrected. Elemental analyses (C , H & N) were
performed by the Microanalysis Laboratory at the University
of Massachusetts, Amerst , MA; phosphorus elemental analyses
were done by the method of Peterson (1978). lH NM spectra
in Me2S0-d6 were obtained at 250 MHz on a Bruker WM2S0
instrument, at 200 MHz on a Bruker AC/P200 instrument, or at
60 MHz on a Perkin Elmer R12B/TT7 Fourier Transform
instrument; 31p NMR spectra in D20 were obtained at 102 MHz
on a Bruker WM2S0 instrument. The 1H NM spectrum at 200
MHz , some 250 MHz spectra, and all 31p NM spectra were
obtained by Steven Freese. Chemical shifts are reported in
ppm relative to external TMS (lH) and external 85% H3P04
31p).
2- 4-Dichloro hen -6-thio uanine (DCTG). A
solution of N 4-dichlorophenyl)guanine (DCPG)l (924 mg,
18 mmol) in pyridine (35 mL) was treated with P2SS (2.
g) .
After 3 h at reflux, the volume of the solution was
reduced about 50% by rotary evaporation. The remaining
solution was poured into water (210 mL), and the resulting
blue-grey precipitate was purified twice by dissolving in 1
N NaOH, treating with charcoal , and precipitating with conc.
HCl. The resulting tan colored solid was dissolved in 1 N
NaOH, and precipitated by adding glacial acetic acid. The
solid was filtered and washed with ethanol, giving 564 mg
(57%) of pale yellow DCTG: mp dec. 220 . C; lH NM: 60 MHz
(Me2S0-d6): 5 10. 62 (s , 1-NH), 9. 34 (s , 2-NH), 8. 32 (s , 8H),
13 (s , 2- H), 7. 98 (m, 5- H, 6- H). Anal.
(C11H7NSCI2S.1. 2H20): Calcd. : C: 39. , H: 2. , N: 20. 98;
Found: C: 39. 91 , H: 2. 60 , N: 20 . 37 .
2- 4-Dichloroanilino -6-meth l thio urine DCMTP
mixture of DCTG (329 mg, 1. 05 mmol) in 10 mL of 0. 1 N NaOH
and 10 mL ethanol was treated with iodomethane (75 ~L, 1.
mmol) in ethanol (2 mL). After 45 min , water was added , and
the solution was chilled, giving a yellow precipitate. The
precipitate was chromatographed on a silica gel column (3 x
1 J. Gambino and G. Wright, unpublished.
5 cm) with a gradient of chloroform to 8% isopropyl
alcohol in chloroform. The product was crystallized from
aqueous ethanol after treating with charcoal, giving 146 mg
(43%) of the reddish-brown colored product DCMTP: mp 267-270
C; 1H NM: 60 MHz (Me2S0-d6): 5 11. 96 (br s, 9-H), 9. 73 (s,
2-NH), 8. 34 (s , 8-H), 8. 11 (s, 2- H), 7. 65 (m, S- H, 6- H),
69 (s, CH3); Anal. (C12H9NSC12S 7SH20): Calcd. : C:
42. 43, H: 3. 12, N: 20. 62; Found: C: 42. 43, H: 2. 99, N:
20. 26.
2- 4-Dichloroanilino -6-methoxypurine DCMP
solution of 2- (3, 4-dichloroanilino) -6-chloropurine (DCACI) 2
(299 mg, 0. 95 mmol) in 10 mL of 1 H sodium methoxide in
methanol was heated at reflux. After 23 h, the reaction
mixture was neutralized by addition of glacial acetic acid
(1 mL), and poured into 50 mL of water. The resulting
precipitate was chromatographed on a silica gel column (2.
x 2. 5 cm). Elution with a gradient of chloroform to 20%
isopropyl alcohol in chloroform yielded one major product
which was crystallized from methanol to give 257 mg (87%) of
nearly colorless DCMP: mp 350 o C; 1H NMR: 60 MHz (Me2S0-
d6): 5 12. 61 (br s, 9-H), 9. 67 (s, 2-NH), 8. 30 (s, 8-H),
8 . 06 ( a, H), 7. 64 (m , 5 - H , 6 - H), 4. 11 ( s , CH 3). Ana 1 .
(C12H9 OCI2 1j3MeOH): Calcd. : C: 44. 26, H: 3. 71, N:
19 . 85; Found: C : 44. 44, H : 3. 53, N : 19. 59 
2 J. Gambino and G. Wright, unpublished.
2-Anilinoadenine 2AA A solution of 2-anilino-6-
chloropurine (ClAP) (Focher et al.
, 1988b) (84. 7 mg, 0. 344
mmol) in methanol saturated with ammonia (5 mL) was heated
in a sealed tube at 130 . C for 4. 5 h. Addi tion of 2 mL of
water precipitated a small amount of a dark solid
, which was
removed by filtration. The filtrate was chilled, and the
solid which precipitated was crystallized from ethanol to
yield 50. 3 mg (65%) of 2AA as a colorless solid: mp 284-288
Ci H NMR: 60 MHz (Me2S0-d6): S 12. 24 (s , 9-H), 8. 69 (s , 2-
NH), 7. 83 (d , o-cpH), 7. 78 (s , 8-H), 7. 21 (t , m-cpH), 6. 85 (m
cpH), 6. 74 (s , NH2) Anal. (C11H10N6.0. 2H20): Calcd. : C:
57 . 48 , H: 4. 56 , N: 36. 56 Found: C: 57. 75 , H: 4. 51 , N:
36. 65.
2- 4-Dichloroanilino
-6- chloro-9- 2-deox S-di-
toluo ribofuranos
urine blocked DCACldR and its
7-isomer. A mixture of 2- (3 4-dichloroanilino) -6-
chloropurine (DCACI)3 (507 mg, 1. 612 mmol) and NaH (50%
suspension in mineral oil
, 77. 4 mg, 1. 6 mmol) in dry
acetonitrile (SO mL) was stirred at room temperature for 30
min. 2-DeoxY-3, S-di-p-toluoYl- ribofuranosYI chloride
(626. 3 mg, 1. 61 mmol) was added in small portions over 40
min, and stirring was continued for 30 min. The mixture was
ii,
diluted with chloroform (SO mL) and filtered through Celite.
The filtrate was evaporated to dryness
, and was purified by
3 J. Gambino and G. Wright , unpublished.
HPLC. The HPLC was equipped with a Waters 6000A pump, a
refractometer detector and a preparative scale silica column
(10 ~M particle size, 2. 2 x SO cm); 10% acetone in toluene
was used as the mobile phase. The column was run at a flow
rate of 13. 5 mL min The 9-isomer eluted between 200 and
253 mL, and the 7-isomer eluted between 331 and 368 
mL. The
9-isomer was crystallized from ethanol to give 712. 5 mg
(66%) : mp 184-188 o C; 1H NMR: 250 MHz (Me2S0-d6): S 10.
( s , 2 - NH), 8. 55 ( s , 8 - H), 6 . 56 (t , l' - H , J a v = S. 7 Hz), 5 . 83
(m, 4' -H), 4. 53 (m , 5' 3' -H), 2. 86 (m , 2' 2" -H); Anal.
(C32H26NSOSC13.0. 2 toluene): Calcd. : C: 58. , H: 4. , N:
10. 22; Found: C: 58. , H: 4. , N: 10. 21. The 7-isomer was
crystallized from ethyl acetate
, giving 171 mg (15%) of a
colorless product: mp 174-175. 5 o C; IH NM: 250 MHz (Me2S0-d6): 5 10. 21 (s , 2-NH), 8. 93 (s
, 8-H), 76 (t , l'-H , Jav =8 Hz), 5. 73 (m , 4'-H), 4. 52 (m , 5' , 5" , 3'-H), 2. 84 (m
2 ' , 2 ' , -H) . Anal. (C32H26NSOsCI3): Calcd. : C: 57. 63, H:
3 . 93 , N: 10. SO; Found: C: 57. 40, H: 4. 06 , N: 10. 47 .
2- 4-Dichloroanilino
-6- chloro-9- 2-deox
ribofuranos
) p
urine DCACldR A solution of blocked
DCACldR (313. 5 mg, 0. 47 mmol) in methanol saturated with
ammonia (20 mL) was stirred in a loosely capped flask for 26
h. The solution was neutralized with glacial acetic acid and
chilled. The precipitate was crystallized from aqueous
ethanol to give 155 mg (77%) of DCACldR as a colorless
sol id: mp 150-153 o C; 1H NM: 250 MHz (Me2S0-d6): 5 10.
(s, 2-NH), 8. 55 (s , 8H), 8. 11 (d , 2- H, J = 2. 0 Hz), 7.
(d, S- , J = 9. 0 Hz), 7. 55 (m, 6- , J = 8. 9 Hz), 6. 34 (t
l'-H, Jav = 6. 6 Hz), 4. 40 (m , 3'-H), 3. 86 (m , 4'-H), 3.
(m, 5' , 5' I-H), 2. , 2. 40 (m' , 2'-H , 2"-H); Anal.
(C16H14NS03CI3 /3EtOH): Calcd. : C: 44. , H: 3. , N:
15. 70; Found: C: 45. 28, H: 3. 30, N: 15. 80.
2- 4-Dichloroanilino
-2' -deox adenosine DCAdA
solution of blocked DCACldR (303 mg, 0. 454 mmol) in methanol
saturated with ammonia (8 mL) was heated in a sealed tube at
130 o c for 6 h. After evaporation of the solution to
dryness , the residue was crystallized from methanol to yield
115 mg (62%) of colorless DCAdA: mp 203-206 o C; 1H NMR: 200
MHz (Me2S0-d6): S 9. 32 (s , 2-NH), 8. 20 (d, 2- H), 8. 12 (s
8H), 7. 77 (dd , 6- , J = 2. 4 Hz , J = 8. 9 Hz), 7. 43 (d , 5-
j = 8. 9 Hz), 7. 15 (s, NH2), 6. 26 (t, l'-H, Jav = 6. 8 Hz),
30 (br s , 3'-OH), 4. 88 (br s , S'-OH), 4. 38 (m , 3'-H), 3.
(d, 4'-H, J = 2. 7 Hz), 3. 53 (t, S' , J = 4. 9 Hz), 2.
28 (m' , 2' , 2' '-H); Anal. (C16H16N603C12 81/2H20): Calcd.
C: 45. , H: 4. 32, N: 20. 00; Found: C: 46. , H: 3. , N:
19. 61.
2- 4-Dichloroanilino
-2' -deox adenosine 5' - hos hate
DCAdAMP A solution of DCAdA previously dried vacuo
(100 mg, 0. 24 mmol) in trimethyl phosphate (1. 3 mL) was
chilled to -4 o c and stirred for 30 min. Phosphoryl
chloride (75 ~L, 0. 8 mmol) was added during 2 h , and
stirring was continued for 4 Cold water (1. 3 mL) was
then added, and the solution was neutralized with 1 M NaOH.
The solution was applied to a DEAE-Sephadex column
(bicarbonate form; 25 x 2. 5 cm), and eluted with a 24 h
linear gradient of 0. 1 to 1. 0 M triethylammonium bicarbonate
at a flow rate of 160 mL h-1 , with the collection of 15 mL
fractions. Fractions # 180 to 247, which contained the
desired product, were pooled and evaporated to dryness. The
residue was dissolved in water, and the solution was
filtered (0. 2 ~m), and lyophilized to give the
triethylammonium salt of DCAdAMP (79 mg, 56%). 31p NM: 102
MHz (D20): S 3. 90 (d, JpH = 4. 6 Hz). Anal.
(C16H17N606C12P. N (Et) 3 J: Calcd. : P: 5. 23; Found: P: 4. 88.
2- 4-Dichloroanilino -2' -deox adenosine 5'-
tri hos hate DCAdATP A solution of DCAdAP (35. 8 mg,
06 mmol) in HMPA (0. 5 mL) was treated at room temperature
with 1, 1'-carbonyldiimidazole (42. 5 mg, 0. 26 mmol). After
stirring for 2 h, this activation step was quenched by the
addition of 38 ~L methanol, and stirring was continued for 1
A solution of tributylammonium pyrophosphate (110 mg,
24 mmol) in HMPA (2 mL) was added dropwise, and stirring
was continued for 24 h. The reaction was quenched by the
addition of 10 mL of cold water. The resulting solution was
applied to a DEAE-Sephadex column (bicarbonate form; 25 x
Iii
5 cm), and eluted with a 24 h linear gradient of 0. 2 to
0 M triethylammonium bicarbonate at a flow rate of 160 mL
, with the collection of 15 mL fractions. Fractions #
142-156, which contained the desired product, were pooled
and evaporated to dryness. The residue was dissolved in
water, and the solution was filtered (0. 2 ~m), and
lyophilized to give the tetrakis (triethylammonium) salt of
DCAdATP (16 mg, 25%). 31p NM: 102 MHz (D20): 5 -6. 04 (d,
P, J = 22. 6 Hz), -11. 01 (m, a-p), -21. 98 (t, -P, Jav = 20.
Hz). Anal. (C16H19N6012CI2 4N(Et) 3): Calcd. : P: 8. 80;
Found: 9. 19.
The following inhibitors were synthesized by others in
the lab of Dr. George Wright, as described: BuA, BuACl,
BuAOMe, BuPTG, BuASMe and BuAdA (Wright et al., 1987);
BuAdATP (Khan et al., 1985); BuPG (wright et al. , 1982);
BuPdG, BuPdGTP (Wright & Dudycz, 1984). The aphidicol in
analogs 17-acetylaphidicolin, 17, 18-diacetylaphidicolin,
"16-ketoaphidicol in" (3 , 18-dihydroxy-17-noraphidicolan-16-
one) and 3-epiaphidicolin were prepared by Dr. Lili
Arabshahi, (Arabshahi et al., 1988) according to the methods
of Dalziel et al. (1973). F2MDP also was prepared by Dr.
Arabshahi, by the method of Blackburn et al. (1981).
EMPdGTP, PhdGTP and HexdGTP were prepared by stephen
Freese. 1 DCAA, DCACI and DCPG were prepared by Joseph
1 S. Freese and G. wright, unpublished.
Gambino. 2 The following inhibitors were synthesized in the
lab of Dr. Charles McKenna (Uni versty of Southern
California), as described: BrPAA, FCIPAA, FBrPAA, CIPPA,
FMDP and COMDP (Talanian et al., submitted), the latter by a
minor variation of the method of Quimby et al. (1967).
AraATP, araCTP, ddTTP, PPi, PFA, PAA, DAP and DAPdR were
purchased from sigma. MDP was purchased from Aldrich.
ACGTP and AZTTP were gifts from Dr. Wayne Miller (Burroughs-
Wellcome Co. FPAA, F2PAA, CIPAA, C12PAA, CIBrPAA, Br2PAA,
COPAA, FPPA, CIPPA, FBrMDP, FCIMDP, CIMDP, C12MDP, CIBrMDP,
BrMDP and Br2MDP were gifts from Dr. Charles McKenna
(University of Southern California) Aphidicolin was a gift
from the Natural Products Branch, National Cancer Institute.
C. Cell Culture and Measurement of Macromolecule
Precursor Uptake and Incorporation
Growth of CHO cells. CHO SCl-9 cells were grown in
suspension culture at 37 o c at densities of 4 to 12 x 10
cells mL -1 , in McCoy' s SA medium supplemented with 10% fetal
bov ine serum. Densi ties were determined by hemocytometer.
Incor oration of TdR into CHO cell DNA.
Incorporation of ( 3H)TdR into CHO cell DNA was measured
essentially as described (Wright et al., 1987).
suspension of exponentially growing CHO cells (4 to 8 x 105
2 J. Gambino and G. Wright, unpublished.
cells mL ) was distributed in 3 mL aliquots into capped
plastic tubes containing drug solutions in Me2S0 or Me2S0
itself as control, and incubated at 37 o c for 3 h with
shaking. 3H)TdR (1. Ci, 20 ci mmol-1 ) was then added to
each tube, and incubation was continued for 30 min.
Incorporation was then quenched by the addition of 3 mL of
ice-cold phosphate buffered saline (PBS) (pH 7. 0), and the
mixtures were centrifuged at 1000 x g for 10 min. The
supernatants were aspirated , and the pellets resuspended in
2 mL of 1 H NaOH. The mixtures were then incubated at 65 o
for 1 h in order to hydrolize RNA, after which 2 mL of an
ice-cold solution of 20% trichloroacetic acid (TCA) (wjv)
and 20 ro sodium pyrophosphate (NaPPi) was added. After
chilling on ice for 15 min, the mixtures were filtered
through GFjA discs (Whatman), and the discs were washed with
a cold solution of 1% TCA (wjv) and 10 ro NaPPi, then with
ethanol, and dried. The discs were transferred to
scintillation vials, 1 mL of Opti-Fluor (Packard) was added
to each, and radioactivity was measured in a scintillation
counter. Control incorporation of ( 3HJTdR per tube was 7000
to 9000 cpm above background, which was typically 100 to 200
cpm.
Incor oration of urd into CHO cell RNA.
Incorporation of ( 3HJUrd into CHO cell RNA was measured as
the difference between total TCA-precipitable counts and
that which remained after base-catalyzed hydrolysis
essentially as described (Wright et al. , 1987).
suspension of exponentially growing CHO cells (4 to 8 x 10
cells mL -1 ) was distributed in 3 mL al iquots into capped
plastic tubes containing drug solutions in Me2S0 or Me2S0
itself as control, and incubated at 37 o c for 3 h with
shaking. 3H)Urd (3 ~Ci , 47 ci mmol-1 ) was then added to
each tube, and incubation was continued for 45 min.
Incorporation was then quenched by the addition of 3 mL of
ice-cold phosphate buffered saline. Aliquots of 1 mL of
each sample were then prepared for measurement of ( 3H)Urd
incorporation into either (1) DNA, or (2) DNA and RNA, as
follows: (1) The mixtures were centrifuged at 1000 x g for
10 min, and the supernatants were aspirated. The pellets
were resuspended in 0. 5 mL of 1 N NaOH, incubated at 65 o
for 1 h , and ( 3H)Urd incorporation was measured as described
above in the case of (3H)TdR incorporation. (2) A solution
of 0. 5 mL of ice-cold 10% TCA (wjv) and 10 ro NaPPi was
added to each tube. The tubes were then chilled on ice for
15 min, after which the mixtures were filtered through GFjA
discs (Whatman), and the discs were washed and counted as
described above in the case of ( 3H) TdR incorporation.
Incorporation of ( 3H)Urd into RNA was calculated as the
difference between the counts obtained by (1) and (2).
Control incorporation of ( 3H)Urd into RNA was 6000 to 9000
cpm above background, which was typically 100 to 200 cpm.
Incor oration of Leu into CHO cell rotein.
Incorporation of ( 3H) Leu into CHO cell protein was measured
essentially as described (Wright et al., 1987).
suspension of exponentially growing CHO cells (4 to 8 x 10
cells mL -1 ) was distributed in 2 mL aliquots into capped
plastic tubes containing drug solutions in Me2S0 or Me2S0
i tsel f as control. 3H)LeU (2 ~Ci , SO Ci mmol-1 ) was then
added to each tube, and the mixtures were incubated at 37 
0 C
for 3 h with shaking. Incorporation was then quenched by
the addition of ice-cold solutions of 100 ~L bovine serum
albumin (BSA) (1 mg mL ) and 200 ~L of 25% (wjv) TCA, and
the tubes were chilled on ice for 15 min. The mixtures were
centrifuged at 1000 x g for 10 min, and the supernatants
were aspirated. The pellets were washed three times by
resuspending in 0. 5 mL of 0. 1 H HCl, centrifuging and
aspirating the supernatant. The pellets were resuspended in
5 mL of 1 H NaOH, and incubated at 60 o c for 30 min. The
solutions were neutralized with conc. HCI, and transferred
to scintillation vials. Aqueous counting scintillant
(Packard) (4 mL) was added, and the radioactivity in each
sample was measured in a scintillation counter. Control
incorporation of ( 3H) Leu was 8000 to 10, 000 cpm above
background, which was typically about 100 cpm.
Measurement of idine U take b CHO cells.
3HJTdR uptake by CHO cells was measured as described by
Aronow and Ullman (1985), with certain modifications.
Exponentially growing CHO cells (4 to 8 x 10
5 cells mL
were centrifuged and resuspended in McCoy' s SA medium
(unsupplemented) containing 10 ~M aphidicolin, at a density
of about 2 x 107 cells mL -1 Drug solutions in Me2S0 or
Me2S0 itself as control were added , and the suspensions were
incubated at 37 o c with occasional agitation for 15 to 45
min. Separately, 1. 5 mL plastic microcentrifuge tubes were
prepared containing 100 ~L of unsupplemented McCoy' s 5A
medium with ( 3H)TdR (10 ~ci mL , 20 ci mmol-1 ) layered over
100 ~L of an oil mixture (silicone oil (Aldrich 17, 563-3) :
light mineral oil (Fisher 0-121), 94: 6) . 100 ~L of the cell
suspension were added to the aqueous layer of the tube , and
after a 15 sec incubation, the tube was centrifuged at
15, 000 x g for 25 sec, causing the cells to pellet below the
oil layer. The aqueous layer was aspirated, and the walls
of the tube were washed twice by addition and aspiration of
o . 5 mL PBS (pH 7. 0) . The oil layer was aspirated, and the
cell pellet was suspended in 0. 1 mL of 2% (vjv) Triton X-
100. 1 mL of scintillation fluid was added, and the samples
were counted. Control uptake of ( 3H)TdR was 7000 to 10, 000
cpm above background.
Incor oration of 32P hos hate into CHO cell DNA.
Incorporation of ( 32pJphosphate (orthophosphate) into CHO
cell DNA was measured essentially as described (Robichaud &
Fram, 1987). A suspension of exponentially growing CHO
cells at a density of about 4 to 8 x 10
5 cells mL -1 ) was
distributed in 2. 5 mL aliquots into capped plastic tubes
containing drug solutions in Me2S0 or Me2S0 itself as
control, and the tubes were shaken at 37 
0 C. After 1 h a
solution of ( 32p)phosphate (12. 5 ~ci, 200 mCi mmol-1) was
added, and shaking was continued. After 3 h, 2. 5 mL of ice-
cold phosphate buffered saline (pH 7. 0) was added, and the
tubes were chilled on ice for 15 min. The mixture was
centrifuged at 1400 x g for 10 min, and the supernatant was
aspirated. Workup and counting were then performed as
described above in the case of ( 3H)TdR incorporation.
Incorporation of ( 32p) phosphate by the control samples was
8000 to 12, 000 cpm above background.
32P dATP incor oration in ermeable CHO cells.
Permebilization of and measurement of DNA synthesis in CHO
cells was performed essentially as described by Dresler
(1984) in the case of human fibroblasts. CHO cells, used at
a density of 4 to 8 x 10 5 cells mL -1 , were prelabelled by
supplementing the cell culture medium with ( 3H)TdR (5 nCi
mL -1 , 20 ci mmol-1 ), in order to control for variations in
the number of cells in each assay tube. Cells were made
permeable by incubation at 0 C for 30 min in a solution of
10 ro Tris (pH 7. 6), 4 ro MgC12' 1 ro EDTA, 250 ro sucrose,
and 3 ro DTT. The cells were washed twice in the same
buffer to remove endogenous nucleotides. 100 ~L of the
permeabl cell suspension (107 cells mL ) was mixed with SO
~L of a reaction mix containing inhibitors in Me2S0 or a
solution of 10 ro HEPES-K , or the solvents themselves as
controls, to give final concentrations of 40 ro Tris (pH
6), 8 ro MgC12' 5 ro ATP, 167 ro sucrose, 2 ro
dithiothreitol, 0. 67 ro EDTA, SO ~M each of dCTP, dGTP and
dTTP and 1 ~M (a-32PJdATP (15 Ci mmol-1 Samples were
incubated at 37 0 C for 8 min, and workup and counting were
performed as described (Dresler, 1984). Control samples
typically incorporated 2000 to 3000 cpm of 32p, and
contained 2000 to 3000 cpm of the 3H prelabel.
D. Enzymes
DNA ol erase delta. PCNA-independent calf thymus DNA
polymerase 5 was provided by Drs. Federico Focher and Ulrich
Hubscher (university of Zurich-Irchel). Two enzyme
preparations were used; one, designated HAP-S, was purified
through step III, hydroxyapatite chromatography (Focher et
al. 1988c). The second preparation, designated FPLC-5, was
purified through step V, FPLC-MonoS chromatography (Focher
et al. 1989). FPLC-5 was not stimulated by the pol 
cofactor PCNA, nor did it contain PCNA (Focher et al.,
1989) . FPLC-& contained four maj or peptides and was used in
the analysis of the mechanism of inhibition of pol 5 by
COMDP, and in assays of exonuclease activity.
DNA erase al ha. Calf thYmus DNA polymerase a was
prepared by Drs. Kimberly Foster and Russell Hammond, using
the immunoaffini ty chromatography method of Chang et ale
(1984) .
other enz Terminal deoxynucleotidyl transferase was
purchased from New England Nuclear.
E. Enzyme Assays
Pol :oli as the tem late: rimer.
pol a and pol 5 (either HAP-5 or FPLC-5) using
Assays of
poly(dA) :oligo(dT) as the template:primer contained the
following in 25 ~L: 75 ro HEPES-K (pH 7. 5), 1. 25 ro DTT,
20% (vjv) glycerol, 10 ro MgC12' 250 ~g mL-1 BSA, 0. 5 ~g
poly(dA) :oligo(dT) (base ratio 10:1), 10 ~M (3HJdTTP (1250
or 2000 cpm pmole ), and about 0. 005 to 0. 02 units of the
enzYme to be assayed. One unit of DNA polymerase activity
is defined as the amount of enzyme which catalyzes the
incorporation of 1 nmole of dTMP in 60 min at 37 D C under
standard assay conditions. The mixtures were incubated at
37 D C for 30 min, and the material which could be
precipitated by TCA was determined as described by Neville
and Brown (1972).
Activated DNA as the tem late: rimer. Assays of pol a
using activated calf thymus DNA as the template:primer
contained the following in 25 ~L: 20 ro potassium phosphate
(pH 7. 2), 1 ro EDTA, 4 ro DTT, 10 ro MgC12' 250 ~g mL
BSA, 50 ~M each of dATP, dCTP and dGTP, 20 ~M ( 3H)dTTP (500
cpm pmole ), 10 ~g DNAse activated calf thymus DNA, and
about 0. 1 to 0. 5 units of enzyme. The mixtures were
incubated at 37 o c for 30 min, and the material which could
be precipitated by TCA was determined as described by
Neville and Brown (1972). Assays of pol 5 (HAP-S) using
activated calf thymus DNA as the template:primer contained
the following in 25 ~L: 75 ro HEPES-K (pH 7. 5), 1. 25 ro
DTT, 20% (vjv) glycerol, 10 ro MgC12' 250 ~g mL-1 BSA, 100
ro KCl, 1 ro GMP or AMP, 25 ~M each of dATP, dCTP and dGTP,
10 ~M ( 3H)dTTP (1250 cpm pmole ), 3 ~g DNAse activated calf
thymus DNA, and about 0. 002 to 0. 005 units of enzyme. The
mixtures were incubated at 37 o c for 90 min, and the
material which could be precipitated by trichloroacetic acid
was determined as described by Neville and Brown (1972).
In some experiments, the dNTP expected to be competitive
with certain inhibitors was omitted, giving a "truncated"
assay (Wright & Brown, 1976). In these assays, in which
sensitivity of the enzyme to inhibition by compounds
expected to be competi ti ve with the omitted dNTP was
maximized (Wright & Brown, 1976), enzyme activity was
typically 25% that observed under "full" assay conditions,
i . e. , in which all four dNTPs were present.
In experiments in which dTTP was the omitted dNTP, (a-
32p)dGTP (1250 cpm pmole ) at 10 ~M served as the labeled
substrate.
Pre aration of exonuclease substrates. The 3' -terminal
end of oligo (dT) 12-18 was labeled by addition of
radiolabelled dNTPs catalyzed by terminal
deoxynucleotidyl transferase. The following components were
incubated at 37 o c for 60 min in a final volume of 100 ~L:
2 M sodium cacodylate , pH 7. 5, 5 ro MgC12' 250 ~M CoC12' 1
ro mercaptoethanol, 100 ~g mL -1 BSA, 100 ~M oligo (dT) 12-
18' 20 units of terminal deoxynucleotidyltransferase , and
either 160 ~M (a- P)dCTP (5 ci mmol-1 ) or 150 ~M ( 3H)dTTP
(20 ci mmol-1
). 
The reaction was terminated by incubation
at 100 o c for 1 min, and the labeled DNA was purified by
chromatography on Sephadex G-25. Given the amount of DNA
used and the specific activity of the added nucleotides , I
calculated that the products of the reaction were
oligo(dT) 12-18 p)dC)0. 33 and oligo(dT) 12-18 3H)dT)0.
The oligonucleotides were hybridized to poly(dA) (base ratio
10: 1 poly(dA) :primer) prior to use as exonuclease
substrates.
Exonuclease assa Assays of the 3' ~ 5' exonuclease
activity of pol 5 were identical to those of the polymerase
activity except that poly (dA) : oligo (dT) 12-18 (( 32p) dC) 0.
or poly(dA):01igo(dT)12-18-(( 3HJdT)0. 3 were substituted for
poly(dA) :oligo(dT) , and (3H)dTTP and GMP were omitted.
Reactions using the mismatched substrate required about
075 (DNA polymerase) units of enzyme and incubation for 
min. Reactions using the properly paired substrate required
about 0. 5 (DNA polymerase) units of enzyme and incubation
for 20 min. Reactions were terminated by addition of 25 ~L
of 200 ro EDTA, and the samples were prepared for
scintillation counting as described by LaDuca et ale (1986).
The samples were spotted onto DE81 discs (Whatman), and
washed three times in so mL of a cold solution of 0. 3 M
ammonium formate (pH 7. 8) and 10 ro NaPPi, then in ethanol
and dried. The discs were transferred to scintillation
vials , 1 mL of Opti-Fluor (Packard) was added to each, and
radioactivity was measured in a scintillation counter.
F. Calculation of Ki Values of DNA Polymerase Inhibitors on
the Basis of Lineweaver-Burk Plot Data
Ki values for inhibition of DNA polymerases were
determined as follows: The data of Lineweaver-Burk plots
(velocity -1 vs. substrate concentration ) were fitted by
least squares regression. The equations of the regression
lines were used to calculate X- and Y-axis (velocity-1 and
substrate concentration-l axis, respectively) intercepts and
line slopes, as appropriate. The slope and intercept values
were used to calculate Ki values by two methods , which
depended on the pattern of inhibition (see below for the
three cases of competi ti ve , noncompeti ti ve and uncompeti ti ve
inhibition) . The Ki values reported in the text are the
arithmetic means of the two calculated values.
Com etitive inhibition. One Ki value was calculated by
plotting the negative inverse of the X-intercepts determined
as described above vs. inhibitor concentration. The data
were fitted by least squares regression, and the negative of
the X-intercept of the regression line so obtained gave a Ki
value A second Ki value was determined by plotting the
slopes of the regression lines of the Lineweaver-Burk plots
vs. inhibitor concentration; the regression line of that
plot was determined, and the negative of the X-intercept of
that line gave a Ki value.
Noncom etitive inhibition. One Ki value was calculated
by plotting the Y-axis intercepts of the regression lines of
the Lineweaver-Burk plots inhibitor concentration.
least squares regression line was determined, and the
negative of the X-intercept of that line gave the Ki value.
The second Ki value was determined on the basis of the Y-
intercept values of the regression lines of the Lineweaver-
Burk plots as described above in the case of competitive
inhibition.
Uncom eti ti ve inhibition. One Ki value was determined
on the basis of the Y-axis intercepts of the regression
lines of the Lineweaver-Burk plots as described above in the
case of noncompeti ti ve inhibition. The second Ki value was
determined on the basis of the X-intercept values of the
regression lines of the Lineweaver-Burk plots as described
above in the case of competitive inhibition.
CHAPTER III
INHIBITION OF MALIAN CELL DNA SYNTHESIS
A. Introduction
ori inal oal of the ect. The original goal of the
proj ect was to explain the sometimes poor correlation
between the potencies of several nucleoside and nucleobase
analogs as inhibitors of the activity of isolated pol a and
as inhibitors of mammalian cell thymidine (TdR)
incorporation. In particular , I was interested in
elucidating the cytotoxic mechanism(s) of 2- (p-
butylanilino) -2' -deoxyadenosine (BuAdA , Figure III-I).
BuAdA inhibited HeLa cell thymidine incorporation with a
potency (ICSO = 1 ~M) (Wright et al. , 1987) about an order
of magnitude greater than its potency as an inhibitor of
isolated CHO cell pol a (Ki = 10-15 ~M) (Khan et al., 1985).
The following is a description of some of the hypothetical
explanations of the inhibitory properties of BuAdA, which
together served as the rationale for the project at its
outset:
( i) Assuming that pol 5 has a role in mammalian DNA
replication, BuAdA might have inhibited that enzyme with
significantly greater potency than pol If so , the
investigation may have uncovered a selective inhibitor
of pol S, and it would have supported a role for the
BuAA (R = NH2) BuPG
BuAOMe (R = OMe)
NH2
HN 
BuPdG 
Figure III-I. Structures of BuA, BuAOMe, BuAdA,
BuPG and BuPdG.
participation of that enzyme in mammalian cell DNA
replication.
(ii) BuAdA might have been metabolized in the cell to forms
which inhibit pol a with greater potencies than BuAdA
itself. Such an observation may have revealed useful
enzymatic syntheses of potent DNA polymerase inhibitors
and it may have led to the discovery of DNA polymerase
inhibi tors of novel structure. The observation would
also have exposed an important caveat in studies
designed to determine the roles of DNA polymerases in
DNA metabolism by the correlation of the 
vitro and 
vivo potencies of nucleobase and nucleoside analog
inhibitors.
(iii) The investigation might have revealed cellular targets
for inhibition other than DNA polYmerases. If so , and
if, for example, the enzyme (s) were potential
chemotherapeutic targets , BuAdA might have served as a
lead compound for the development of chemotherapeutic
agents.
totoxicit of com ounds other than BuAdA. As the
investigation progressed, I became interested in the
cytotoxic mechanisms of some compounds other than BuAdA.
most cases , such as that of 2-anilinoadenine (2AA), the
compounds were selected because of their structural
relationship to others , and were included in certain
experiments as controls for the contributions of certain
functional groups to their potencies. I studied the
cytotoxicity of 2- 4-dichloroanilino)adenine (DCAA) and
certain analogs thereof because of its potent cytotoxicity
to mammalian cells1 and its structural similarity to known
pol a inhibitors such as the 2-
(p-
n-butylanilino) purines.
These analogous compounds were tested in some but not all of
the experiments described below.
B. Development of Novel Inhibitors Based on DCAA
I synthesized several analogs of DCAA during the course
of the work described below, with the goal of finding
compounds which display increased potency as inhibitors of
cellular DNA synthesis , isolated DNA polymerase activity, or
both, relative to DCAA. For clarity, I describe the
syntheses of all of the DCAA analogs in this section
regardless of the order in which I synthesized them or the
timing of the syntheses with respect to the experiments
described in subsequent sections.
Nucleobase analo s of DCAA. Several analogs of the
corresponding base analog of BuAdA, \2- (p-n-
butylanilino) adenine (BuA, Figure III-I), differing from
BuA in the nature of the substituents in the 6-position of
the purine base, were more potent inhibitors of CHO cell pol
1 P. Medveczky and G. Wright , unpublished.
a than BuA (Wright et al., 1987). The latter observation
suggested by analogy that similar 6-substituted analogs of
DCAA might possess greater inhibitory potency than DCAA.
therefore synthesized 6-methoxy (2- (3, 4-dichloroanilino) -6-
methoxypurine, DCMP, Figure 111-2) and 6-methylthio (2-
dichloroanilino) -6-methylthiopurine, DCMTP, Figure 111-2)
analogs of DCAA, as well as the intermediate 6-thio (N
(3, 4-dichlorophenyl)-6-thioguanine, DCTG, Figure 111-2) and
6-chloro (2- (3, 4-dichloroanilino) -6-chloropurine , DCACl,
Figure 111-2) analogs. Figure 111-2 outlines the syntheses
of the latter compounds from the corresponding guanine
analog (N2_(3, 4-dichlorophenyl) guanine , DCPG, Figure 111-2);
details of the syntheses are described in Chapter II.
presence of the methyl group resonances in the 1H 
The
spectra of DCMP and DCMTP, and the chemical shifts of other
resonances , served to identify the latter reaction products.
nthesis of 2AA. In several experiments described
below , I wished to demonstrate the role of the substi tuents
on the anilino rings of DCAA and BuAA (3, 4-dichloro and p-n-
butyl groups, respectively). To do so , I measured the
inhibitory potency of 2AA, a compound which is structurally
identical to DCAA except that it lacks the anilino ring
substituents of DCAA and BuA. I synthesized 2AA from 2-
anilino-6-chloroadenine (ClAP, Figure 111-3) (Focher et al.,
1988b), as outlined in Figure 111-3. The singlet at S 6.
HN:J
CI !SC
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Figure III-2.
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MeI
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Outline of the syntheses of DCAA and
several DCAA analogs from the common
intermdiate DCPG. Each synthesis 
described in detail in Chapter II.
6 C:AP
NH3
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2AA
Figure 111-3. Synthesis of 2AA from ClAP.
The reaction is described in
detail in Chapter II.
in the NM spectrum of 2AA served to identify the compound
as a 2-amino derivative of the starting material, ClAP.
Nucleoside analo s of DCAA. The observation that
nucleoside analogs of BuAA, such as BuAdA , inhibit CHO cell
growth and ( H)TdR incorporation with at least an order of
magni tude greater potency than BuA suggested by analogy
that nucleoside analogs of DCAA might also be more potent
inhibitors than DCAA. I therefore synthesized 2- (3
dichloroanilino) -6-chloro-9- (2-deoxy- -D-
ribofuranosyl) purine (DCACldR) and 2- (3 4-dichloroanilino)-
2' -deoxyadenosine (DCAdA); DCAdA served both as an inhibitor
and as an intermediate in the synthesis of nucleotidyl forms
of DCAA (see below). Figure 111-4 describes in outline form
the syntheses of DCACldR and DCAdA. Isolation of the major
(66%) 9- and minor (15%) 7- isomers was consistent with
the results of similar glycosylations of 6-chloropurines
(Kazimierczuk et al., 1984; Wright et al. , 1987). The
blocked intermediates 2- (3 4-dichloroanilino) -6-chloro-9- (2-
deoxY-3 , S-di-p-toluoyl- D-ribofuranosyl) purine (blocked
DCACldR) and its 7-isomer were identified by proton 
spectra. Resonances corresponding to the toluyl blocking
groups were present. Characteristic pseudotriplet
resonances at S 6. 56 and 6. 76, respectively, due to the 1'-
protons, identified the products as anomers. The relative
chemical shifts of the l' - and 8-position protons served to
l.:r:
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Figure 111-4. Outline of the synthesis of DCAdA from its
corresponding base analog DCAA. Each step
is described in detail in Chapter II.
distinguish between the 9- and 7-isomers (Kazimierczuk et
al., 1984; Wright et al. , 1987). The pseudotriplets for the
l' - proton resonances of DCACldR and DCAdA confirmed the
identity of the latter compounds as 
-isomers.
Nucleotide analo s of DCAA. The deoxyribonucleoside 5'
triphosphate form of BuA (BuAdATP) inhibited CHO cell pol a
with a potency approximately four orders of magnitude
greater than BuA (Khan et al., 1985). The latter
observation as well as similar observations on the
inhibitory potencies of the guanine analogs of BuA and
BuAdATP (N2- (p-n-butylphenyl) guanine, BuPG , Figure III-I
and BUPdGTP) prompted me to synthesize the corresponding
nucleoside 5' -triphosphate of DCAA (2- (3
dichloroanilino) -2' 
-deoxyadenosine 5' -triphosphate
, DCAdATP
Figure 111-5) for testing as an inhibitor of purified DNA
polymerases alpha and delta (see Chapter IV). The synthesis
of DCAdATP from DCAdA, through the intermediate 5'-
monophosphate (2- (3, 4-dichloroanilino) -2' 
-deoxyadenosine 5'
monophosphate, DCAdAP, Figure 111-5) is outlined in Figure
111-5. The presence of a triplet in the 31p NM spectrum of
DCAdAP, due to coupl ing of the phosphorus with the 5' and
5" protons , served to confirm that the monophosphate
product was the 5' phosphate isomer. The observation of a
pseudotriplet in the phosphorus resonance of the 31p NM
spectrum of DCAdATP confirmed that that compound was the
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Figure III-5. Outline of the syntheses of nucleotidyl
forms of DCAA. Each reaction is described
in detail in Chapter II.
triphosphate analog of the starting material DCAdAMP , and
therefore, the 5' -triphosphate derivative of DCAdA.
C. Inhibition of CHO Cell Macromolecule Precursor
Incorporation
Choice of CHO cells. I chose to study the cytotoxic
mechanisms of BuAdA and related compounds in CHO cells
rather than continue the work begun by Wright et ale (1987)
in HeLa cells for two reasons. First , the availability in
our lab of CHO cell pol a , as well as information on the
inhibi tory properties of BuAdA and analogs thereof toward
that enzyme (Khan et al. , 1984; Khan et al. , 1985; Wright et
al., 1987), would have allowed comparison between the
inhibitory properties of compounds toward mammalian cells
and pol a derived from the same source. Second , the
availability of a variety of mutant CHO cell lines (for
example , purine auxotrophs) may have facilitated studies
designed to elucidate of cytotoxic mechanism(s) of BuAdA.
Potencies of adenine analo s as inhibitors of CHO cell
macromolecule recursor incor oration. I measured the
potencies of BuAdA and several other adenine analogs as
inhibitors of incorporation of (3H)thymidine (( 3H)TdR),
H)uridine (( H)Urd) and ( H)leucine ((3H)Leu) into CHO
cell DNA, RNA and protein, respectively, by the techniques
described in Chapter II. The results are summarized in
Table III-I, and are discussed below.
BuAA BuAdA DCAA and DCAdA. The pol a inhibitors BuA
and BuAdA inhibited ( H)TdR incorporation by CHO cells with
ICso values of 15 and 3 ~M , respectively (Table III-I), in
rough agreement with the corresponding values of 23 and 1 ~M
previously determined by Wright et al. (1987) in HeLa cells.
Neither BuA nor BuAdA inhibited ( H)TdR incorporation with
significant selectivity relative to ( H)Urd incorporation;
both compounds inhibited incorporation of the latter
precursor into cellular RNA with ICSO values of 10 
~M. BuA
and BuAdA inhibited ( 3H)Leu incorporation into protein
weakly compared with their effects on ( H)TdR and (3H)Urd
incorporation; BuA displayed an IC50 value 100 ~M , and
BuAdA was inactive at concentrations up to 200 
~M. DCAA , an
inhibitor of pol a with a potency similar to that of BuAA
but with little selectivity compared to pol S (see Chapter
, esp. Table IV-I), and its deoxyribonucleoside
derivatives DCAdA and DCACldR, inhibited ( H)TdR
incorporation by CHO cells with ICSO values similar to those
displayed by BuA and BuAdA. Like the butylanilino-
substi tuted compounds , the nucleosides DCAdA and DCACldR
were more potent inhibitors of ( H) TdR incorporation than
was the corresponding nucleobase, DCAA.
structure-activit relationshi overnin the C totoxic
otencies of 2-anilinoadenine derivatives. I measured the
Iii
ii!
Table III-I. Inhibition of ( 3H)TdR, ( 3H)Urd and ( H)Leu
Incorporation into CHO Cell Macromolecules
IC50 (~M) 2
Inhibi tor (3H) TdR (3H)Urd (3H) Leu
BuAA 100
BuAdA
DCAA
DCAdA
DCACldR
2AA 150
DAP
DAPdR
1Incorporation of (3H)TdR
, (
H)Urd and ( H)Leu into CHO
cell DNA, RNA and protein, respectively, was measured as
described in Chapter II. CHO cells were incubated withinhibitors (or solvent control) for 1 h , then ( H)TdR,3H)Urd or ( H)Leu was added, and incubation was continued
for 30, 45 or 180 min, respectively.
2ICsO values were determined on the basis of inhibitor
concentration vs. percent activity curves. I = inactive at
200 ~M, the highest concentration tested. N = not measured.
S = stimulation of macromolecule precursor incorporation.
3DAP at 200 ~M stimulated incorporation of (
H)Urd 74%
relative to controls.
4DAPdR at 40 ~M stimulated incorporation of (
H)Urd 152%
relative to controls.
inhibi tory properties of several compounds chosen to
demonstrate the significance of the 2-substituents of BuA
DCAA and derivatives thereof. 2AA is a nucleobase analog
structurally identical to BuA and DCAA , except that it
lacks substituents on the phenyl ring of its anilino group.
The relative weakness of 2AA as an inhibitor of CHO cell
H)TdR incorporation (ICso = 150 ~M; Table III-I) compared
to the corresponding values for BuA and DCAA , demonstrated
the importance of the p-n-butyl and the 3- and/or 4-chloro
groups of BuA and DCAA, respectively, to the potencies of
the latter compounds. The cytotoxic drug 2 , 6-diaminopurine
(DAP, Figure 111-6) (Burchenal et al. , 1949), and its
corresponding 2' -deoxyribonucleoside (2- amino-2'-
deoxyadenosine , DAPdR, Figure 111-6), represent structural
controls for the contribution of the phenyl rings and their
substituents in BuA
, DCAA and their derivatives to their
inhibi tory potencies. DAP, once considered for clinical use
as an anticancer agent (Burchenal et al.
, 1949) most likely
exerts its short term cytotoxicity (over a few hours) by
inhibition of purine de novo biosynthesis (Heidelberger &
Keller, 1955; Gots & Golub
, 1959) after metabolism to the
corresponding ribonucleoside 5' -monophosphate (steglich &
DeMars , 1982). The mechanism of cytotoxicity of DAPdR is
unknown. Both DAP and DAPdR were ineffective as inhibitors
of CHO cell (3H)TdR incorporation under conditions where
DAP
NH2
DAPdR
Figure III-6. Structures of DAP and DAPdR.
BuA and DCAA were potent (Table III-I), and both caused
significant stimulation of ( H)Urd incorporation (Table 111-
1) . The observations of stimulation of (3H)Urd
incorporation are consistent with the proposed cytotoxic
mechanism of DAP; in the short term, the cells might adapt
to inhibition of de novo purine biosynthesis by relying more
heavily than usual on polynucleotide precursors taken up
from the cell culture medium, resulting in stimulation of
incorpora tion. It is unclear why (3H)TdR incorporation is
not similarly stimulated. Clearly, however , the inhibitory
properties of DAP and DAPdR argue that the substituted
phenyl groups of BuA, DCAA and their derivatives cause the
latter compounds to act on cells by mechanisms distinct from
those of DAP and DAPdR. The contribution of the 2-anilino
substi tuents of BuAdA and DCAdA to their cytotoxicity was
demonstrated by the lack of effect of deoxyadenosine (dA) on
CHO cell (3H)TdR incorporation at concentrations up to 200
~M (Table III-I).
Time course of inhibition of CHO cell TdR
incor oration b BuAA BuAdA and DAP. To gain insight into
the mechanism of cytotoxicity of BuA and BuAdA, I measured
the degree of inhibition of CHO cell ( H)TdR incorporation
by BuA , BuAdA and, for comparison
, DAP , as a function of
time of exposure to the inhibitors. The cells were
incubated in the presence of inhibitors for various times
after which ( H) TdR was added and incubation continued for
15 min. Incorporation was then quenched, and measured as
descr ibed in Chapter I I . The results are summarized in
Figure 111-7. Inhibition of ( H)TdR incorporation by BuA
and BuAdA was rapid in onset , and the degree of inhibition
did not significantly change with time during 320 min of
inhibi tor exposure. In contrast, a lag time of about 2 h
preceded inhibition by DAP. In addition , the effect of DAP
appeared gradually during several hours , whereas the initial
effects of BuA and BuAdA were maximal. The absence of an
analogous lag time for inhibition by BuA and BuAdA argues
that the latter compounds inhibit CHO cell ( H)TdR
incorporation by mechanisms substantially different from
that of DAP; for example, BuA and BuAdA may not require
metabolism to active forms.
Reversibilit of inhibition of CHO cell TdR
incor oration b BuAA and BuAdA. I determined the
reversibility of the inhibitory effects of BuA and BuAdA on
CHO cell ( H)TdR incorporation by measuring cumulative
H)TdR incorporation before , during and after exposure of
cells to inhibitors. CHO cells were incubated in the
presence of (3H)TdR for 5 h. Inhibi tors or solvent
control) were added to the culture medium at t = 1 h, and
were removed at t = 2 h by twice washing the cells with PBS
(pH = 7. 0) and replacing the culture medium with fresh
Control
. OAP 200,uM
BuM 50,uM
.--
BuAdA 20 
,uM
120 180 240 300
Time (min)
Figure III-7. Time course of inhibition by BuAA,
BuAdA and DAP of CHO cell ( 3H)TdR incorporation. Cells were
incubated with inhibitors for various times. At the
indicated times, (3H) TdR was added, and incubation was
continued for 15 min. Incorporation was then quenched, and
measured as described in Chapter I 
I!I
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cuI ture medium. Incubation was then continued for 3 
various times, aliquots of cells were removed, incorporation
was quenched and ( H) TdR incorporation was measured as
described in Chapter II. The results are presented in
Figure 111-8. At t = 2 h, the end of the hour of drug
exposure, significant inhibition of ( H)TdR incorporation by
both BuAA and BuAdA was apparent, as expected. After t = 2
h, the rate of ( H)TdR incorporation by mock-treated cells
(controls) had decreased substantially. The decrease was
likely due to the sudden change from conditioned to fresh
culture medium when the inhibitors were removed. At t = 5
h, 3 h after the inhibitors were removed, the cells
previously exposed to BuA or BuAdA were incorporating
3H) TdR at rates at least as great as that of the mock-
treated cells. That observation indicated that there was no
residual effect of exposure to the inhibitors; inhibition of
3H) TdR incorporation was completely reversible on removal
of the inhibitors. The latter conclusion served as evidence
against the hypothesis that BuA, BuAdA or both are
metabolized within CHO cells to more potent forms. For
example, if BuAdA were metabolized to any of its 5'-
phosphate forms, which inhibit DNA polymerase alpha with 10
to 1000-fold greater potency than BuAdA (Khan et al. , 1985),
the membrane impermeability to those metabolites would
I ikely not have resulted in the observed reversibil i ty .
/ .-- 
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Figure III-8. Reversibility of inhibition by BuAA
and BuAdA of CHO cell (3H) TdR incorporation. Cells were
incubated in the presence of (3H) TdR. At t = 1 
inhibitors were added, and removed at t = 2 h by twice
washing the cells with phosphate buffered saline, and
resuspending in fresh medium. Samples of cells were removed
at the indicated times, and incorporation was quenched and
measured as described in Chapter I 
D. Mechanism of Inhibition of Thymidine Incorporation
Inhibition of TdR u take. I began investigating the
mechanism of nucleobase and nucleoside analog inhibition of
3H)TdR incorporation by examining the inhibitory effects of
BuA, BuAdA, DCAA, DCAdA and other compounds on the
metabolic steps required for (3H) TdR incorporation. As the
first mediated step in the overall process of incorporation
of extracellular ( H)TdR into DNA, I first considered
3H) TdR transport across the cell membrane as a potential
target for inhibition. I adapted the technique of Aronow
and Ullman (1985) to measure short term (3H)TdR uptake by
CHO cells in the absence of replicative DNA synthesis.
Uptake is defined as the sum of transport across cell
membranes plus metabolism to forms which cannot diffuse out
of the cell, such as nucleotides and polYmers (Cass and
Paterson, 1977). Thus , nucleoside transport per se can only
be measured in the absence of nucleoside metabolizing
enzymes , for example in a reconstituted system.
therefore , measured nucleoside uptake , and controlled for
the likely possibility that one or more of the inhibitors in
question block ( H) TdR incorporation at least partially as a
resul t of inhibition of DNA polymerases by doing so in the
absence of replicative DNA synthesis. I completely
inhibited replicative DNA synthesis by adding 10 ~M
aphidicolin to the cells before measuring ( H) TdR uptake
(Huberman, 1981) At this concentration
, total measured
uptake decreased by 10 to 15%. Finally, background counts
were estimated as the residual counts observed in the
presence of both aphidicolin and the nucleoside transport
inhibitor nitrobenzylthioinosine (NBMPR) at 10 ~M
, a
concentration several orders of magnitude above its ICSO
(Wohlhueter et al.
, 1978). The background so measured
typically represented 20% of the total apparent uptake.
Using the experimental conditions described above
, I
examined the potencies of several compounds as inhibitors of
H)TdR uptake; the results are presented in Table 111-2.
Both of the deoxyadenosine analogs BuAdA and DCAdA
strongly inhibited H) TdR uptake the latter with an IC50
value
~M) comparable to that which it displayed for
inhibi tion of ( H) TdR incorporation (7 ~M; Table III-I).
These observations suggest that much of the inhibitory
potencies displayed by BuAdA and DCAdA in the (3
H) TdR
incorporation assay (Table III-I) may be a result of
inhibition of (3H)TdR transport and phosphorylation
i. 
uptake , rather than inhibition of the replicative DNA
polymerase (s) . The requirement of the 2-anilino
substituents of BuAdA and DCAdA to their potencies as
inhibi tors of (3H) TdR uptake was demonstrated by the
inactivity of dA in the uptake assay. Uptake inhibition
also was strongly dependent on the presence of the
Table 111-2. Inhibition of (3H)TdR Uptake by CHO Cells in
the Absence of Replicative DNA synthesis
Inhibi tor ICSO (~M) 2
BuA
BuAdA
DCAA
DCAdA
BuPdG
2AA
200
100
150
1 (3H) TdR uptake by CHO cells during 15 sec exposure was
measured as described in Chapter II. Net uptake was that
which occured in the presence of, 10 ~M aphidicolin and could
be blocked by 10 ~M NBMPR.
2ICsO values were determined on the basis of inhibitor
concentration vs. percent activity curves. I = inactive at
200 ~M, the highest concentration tested.
1)1
deoxyribofuranosyl group, as shown by the weak inhibitory
potencies of the nucleobase analogs BuA and DCAA , and the
inactivity of 2AA (Table 111-2). The relatively weak
activity of the corresponding deoxyguanosine analog of BuAdA
- (p-
n-butylphenyl) -2' -deoxyguanosine
, BuPdG , Figure 111-
1) in the uptake assay demonstrated the importance of the 6-
substi tuent of BuAdA to its potency.
E. Inhibition of (32p)Phosphate Incorporation into
CHO Cell DNA
The results described in the previous section indicated
that (3H)TdR was an unfortunate choice as a DNA precursor
for the estimation of inhibition of CHO cell DNA synthesis
by 2-substituted purine nucleobase and nucleoside analogs.
The ability of BuAdA and DCAdA to inhibit CHO cell (3H)TdR
uptake (ICSO values of 23 and 4 ~M
, respectively; Table 111-
2) may substantially contribute to or explain the potencies
of .these compounds as inhibitors of CHO cell (3H)TdR
incorporation. Thus , BuAdA and DCAdA may be significantly
weaker inhibitors of cellular DNA synthesis than previously
bel ieved. I therefore chose to reassess the potencies of
those and related compounds as inhibitors of cellular DNA
synthesis.
In order to bypass the effects of inhibitors on
nucleoside uptake, I used the method of Robichaud and Fram
, ,
(1987), which is described in Chapter II, to measure
32p)phosphate incorporation into CHO cell DNA. The use of
phosphate as the radiolabelled DNA precursor has the
advantage that it does not require the activity of several
potential inhibitory targets such as nucleoside transport
proteins. The disadvantages of ( p)phosphate incorporation
include the requirement of several hours of incubation
before cellular DNA is significantly labeled, as
demonstrated by the data of Figure 111-9
, in which
p)phosphate incorporation into CHO cell DNA is plotted as
a function of time of exposure to the label. The curve
clearly demonstrates that there is a lag time of about 60
min before DNA is significantly labeled. Therefore, cells
were exposed to inhibitors (or solvent control) for 1 
after which (32p)phosphate was added. Three hours later
incorporation was quenched, and samples were prepared for
scintillation counting as described in Chapter II. That
portion of base stable , acid precipitable counts whose
formation could be blocked by 10 ~M aphidicolin (typically
80% of the total) was taken as representing replicative DNA
synthesis.
The results of the inhibition studies are presented in
Table 111-3. The purine nucleobase analogs BuA and DCAA
were significantly more potent than their 2'-
deoxyribonucleoside counterparts (BuAdA and DCAdA) as
180
Figure 111-7. Incorporation of (32p) phosphate into
indicated.
120
Time (min)
CHO cell DNA as a function of time of exposure to the label.
(32p) Phosphate incorporation was measured as described in
Chapter II, except that incubation time was varied as
Table 111-3. Inhibition of Incorporation of ( 32p)Phosphate
into CHO Cell DNA1
Inhibi tor ICSO (~M) 2
DCAA
BuAOMe
DCMTP
DCMP
DCACI
BuA
DCAdA
DCTG
BuPTG
BuACI
BuAdA
BuASMe
DCPG
BuPG
BuPdG
100
1 ( 32 P) Phospha te incorporation into CHO cell DNA was
measured as described in Chapter II. Cells were incubated
with inhibitors (or solvent control) for 1 h, (32p)phosphate
was added , and incubation was continued for 3 h. Thatportion of radiolabelled , base stable , acid precipitable
macromolecules whose synthesis could be blocked by
aphidicolin was taken as representing net DNA synthesis.
ICSO values were determined on the basis of inhibitor
concentration vs. percent activity curves. I = inactive at
100 ~M, the highest concentration tested.
inhibitors of (32p)phosphate incorporation. The activities
of BuAdA and DCAdA in the ( 32p)phosphate incorporation assay
(with IC50 values of 80 and 35 ~M, respectively), compared
to their activities in the (3H)TdR incorporation assay (IC50
values of 3 and 7 ~M, respectively), were consistent with
the proposal made earlier that one or both of the compounds
inhibi ts CHO cell ( 3H) TdR incorporation largely as a result
of inhibition at targets not directly related to DNA
synthesis , for example, nucleoside transport proteins. The
most potent inhibitor in the ( p)phosphate incorporation
assay was DCAA (ICSO 12 ~M; Table 111-3), a compound that
inhibited ( 3H)TdR uptake with an ICsO value of 100 ~M (Table
111-2) and inhibited ( 3H)TdR incorporation into CHO cell DNA
with an ICsO value of 20 ~M. The latter results suggest
that DCAA, unlike DCAdA and BuAdA, inhibited (32p)phosphate
and ( 3H)TdR incorporation by CHO cells as a result of
inhibition of DNA synthesis, possibly by direct inhibition
of the replicative DNA polymerase (s) .
I tested several 6-substi tuted analogs of DCAA for
inhibition of ( 32p)phosphate incorporation by CHO cells.
The rationale for testing these compounds was that the
members of an analogous series of BuAA derivatives were more
potent inhibitors of CHO cell pol a than BuA itself (Wright
et al., 1987); 6-substitution of DCAA might have resulted in
one or more compounds with greater inhibitory potency toward
pol a (or perhaps pol 5), or toward DNA synthesis. The
results (Table 111-3) indicated that none of the DCAA
analogs was a more potent inhibitor than DCAA itself. The
guanine analog of DCAA (DCPG) was completely inactive in the
32p)phosphate incorporation assay; in fact, all of the
guanine analogs tested were weaker inhibitors than their
adenine analog counterparts. The data of Table 111-3 are
consistent with the observations of Wright et al. (1987),
who found that, in the case of BuA analogs , adenine analogs
were generally more potent than their guanine analog
counterparts , and that 6-substituted BuA analogs , despite
their increased potency as inhibitors of pol a
, were
generally less potent inhibitors of CHO cell (3H)TdR
incorporation than BuA.
CHAPTER IV
INHIBITION OF MALIAN DNA POLYMERASES ALPHA AND DELTA
A. Introduction
In Chapter III, I described the investigation of the
mechanism of inhibition of CHO cell (3H) TdR incorporation by
BuAdA, a compound which inhibited CHO cell (3H)TdR
incorporation more potently than pol a (Wright et al.
1987). During that investigation, I found that the potency
of inhibition of (3H)TdR incorporation by BuAdA could
largely be explained by its ability to inhibit ( H)TdR
uptake rather than DNA synthesis. I reassessed inhibition
of cellular DNA synthesis using (32p)phosphate rather than
3H) TdR as the labeled precursor, and found that BuAdA
, like
all of the BuA analogs which have been tested (Wright et
al. , 1987), is a weaker inhibitor of cellular DNA synthesis
than of pol During the course of the work described in
Chapter III , it was reported that BUPdGTP
, an inhibitor of
pol a with nanomolar range potency (Khan et al 1984), and a
degree of selectivity of about three orders of magnitude for
pol a compared to pol S (Lee et al., 1985), inhibited
permeable cell DNA synthesis with a potency two to three
orders of magnitude less than its potency as an inhibitor of
pol a (Dresler & Frattini
, 1986; 1988). The latter result
fit the pattern that inhibitors selective for pol a relative
to pol 5, unlike inhibitors such as aphidicolin which do not
discriminate between the two enzymes (Goscin & Byrnes
1982), inhibit cellular DNA synthesis significantly more
weakly than they do pol This observation suggested (i) 
role for pol 5 in cellular DNA synthesis , and (ii) that
inhibi tion of pol S, perhaps in addition to inhibition of
pol a, is the maj or requirement for inhibition of cellular
DNA synthesis. An inhibitor of pol 5 selective for that
enzyme relative to pol a could be used to test both of the
latter hypotheses, although such a compound was not known.
I therefore began a search for a selective inhibitor of pol
The search for, discovery of, and characterization of
the inhibitory mechanism of one such compound is the topic
of the present chapter. The subsequent chapter , V, which
completes the " results" section of the thesis , describes
experiments designed to reveal the effects of the selective
pol 5 inhibitor on cellular DNA synthesis.
B. Enzymes.
Calf th us DNA erase al ha. Pol a from cal 
thymus was prepared by Drs. Kimberly Foster and Russell
Hammond (Uni versi ty of Massachusetts Medical School), by the
immunoaffinity chromatography method described by Chang et
al. (1984). Pol a so prepared was composed of four maj or
peptides, as judged by SDS-polyacrylamide gel
electrophoresis. The preparation contained two enzyme
activities: a DNA polymerase and a DNA primase.
Cal f mus DNA ol erase delta. Pol 5 from calf
thymus DNA was prepared by Drs. Federico Focher and Ulrich
Hubscher (University of Zurich-Irchel). I used two enzyme
preparations, which differed in their degree of purity.
One, designated HAP-S , was purified as described (Focher et
al., 1988c), through step III, hydroxyapatite
chromatography. HAP-S was composed of four maj or peptides
and several others of lower abundance, as judged by a SDS-
polyacrylamide gel electropherogram stained with Coomassie
blue. The second preparation, designated FPLC-S
, was
purified as described (Focher et al. , 1989), through step V
FPLC-monoS chromatography. FPLC-S was composed of four
major peptides. FPLC-5 became available to me late in the
course of the experiments described here, and I used it only
in the analysis of the mechanism of inhibition of pol S by
carbonyldiphosphonate (COMDP) (section IV-E below) . Both
HAP-5 and FPLC-5 contained two enzyme activities: a DNA
polymerase and a 3' ~ 5' exonuclease. Neither FPLC-S
(Focher et al., 1988c) nor HAP-S 1 were stimulated by PCNA.
Western blots using a PCNA-specific heteroantiserum
(Almendral et al., 1987) indicated that PCNA was not present
in either HAP-5 (Focher et al. , 1988c) or FPLC-S (Focher et
1 U. HUbscher
, personal communication.
al., 1989). Calf thymus is the only tissue from which both
PCNA stimulated (Lee et al. , 1984) and PCNA insensitive pol
S forms (Crute et al. , 1986; Focher et al., 1988c) have been
isolated.
C. Screening for Inhibitors of DNA Polyrerases
Alpha and Delta.
DNA ol erase assa conditions. To screen for
inhibition of pol a and pol 5, I used activated DNA as the
template: primer. Because activated DNA is comprised of all
four dNMP monomers , its use allowed omission (truncation) of
any of the dNTP substrates, an approach which increases the
sensi ti vi ty of the DNA polymerase reaction to inhibition by
compounds which bind to the enzyme competi ti vely with the
omitted dNTP (Wright & Brown, 1976). Another advantage of
the truncated assay is that , in the absence of the
competitive dNTP, the Ki value of an inhibitor is measured
directly as the IC50 value obtained from a drug
concentration vs. enzyme activity curve (Wright & Brown
1976) . The disadvantage of activated DNA as the
template:primer for the present studies is that it directs a
level of DNA synthesis by pol S which is only about 25% that
directed by the template: primer preferred by pol S
poly(dA) :oligo(dT) (Focher et al. , 1988c). In addition
truncation of the assay decreases DNA synthesis catalyzed by
pol S to about 60% of the value which occurs under full
assay conditions (all four dNTPs present). In order to
increase the activity of pol 5 on activated DNA under
truncated conditions , I doubled the amount of enzyme used
per assay tube and modified the reaction conditions. The
modifications were: (i) an increase in KCI concentration
from 10 to 100 ~M , (ii) an increase in the reaction time
from 30 to 90 min , and (iii) addition of 1 ro GMP or AMP, in
order to inhibit the 3' ~ 5' exonuclease activity of pol 
(Byrnes et al., 1977). wi th these changes , DNA synthesis
catalyzed by pol S under truncated conditions gave
incorporation of 2000 cpm of the radiolabel per assay tube;
enough to give a usable signal to noise ratio 10) when the
enzYme was significantly inhibited.
Screenin of com ounds for inhibition of DNA ol erases
ha and delta. I assayed pol a under the same conditions
as pol I found that pol a catalyzes a level of DNA
synthesis under pol 5 conditions similar to that which it
catalyzes under typical pol a conditions. I measured the
inhibitory activity against pol a and pol 5 of several
nucleotide, nucleoside, purine base and aphidicolin analogs
at 100 ~M in appropriate truncated assays , and pyrophosphate
analogs at 100 ~M in a full assay. The results are
presented in Table IV-I, and are discussed below.
dATP analo None of the dATP analogs tested displayed
Table IV-I. Screen of Compounds for Inhibition of DNA
PolYmerases Alpha and Delta Assayed on
Activated DNA
% Inhibition
Inhibi tor pol a pol 
-dATP
araATP
BuAdATP
BuA
BuAOMe
DCAA
DCACI
DCMP
DCMTP
DCAdA
DCAdAP
DCAdATP
-dGTP
BuPdGTP
EMPdGTP
PhdGTP
HexdGTP
ACGTP
-dCTP
araCTp
Aphidicolin
17-Acetylaphidicolin
17, 18-Diacetylaphidicolin
3-Epiaphidicolin
"16-Ketoaphidicolin"
-dTTP
AZTTP
ddTTP
Full Assay
araCTp2
PPi
PFA
F2MDP
1Enzyme activities (pol and HAP-5) were assayed under
the conditions described in Chapter II for activated DNA as
the template: primer. Enzymes were assayed under full (all
four dNTP substrates present) or truncated (one dNTP
omitted) conditions , as indicated. Inhibitors were present
at 100 ~M unless noted otherwise.
araCTP was assayed in the presence and absence of dCTP.
Inhibitor present at 10 
~M.
selective inhibition of pol S compared to pol a (Table IV-
1) . Because of the high concentration used in the screen
the selectivity of BuAdATP for pol a compared to pol S is
grossly understated by the results presented in Table IV-I.
The Ki values for BuAdATP for the two enzymes
, determined on
the basis of concentration vs. enzyme acti vi ty curves , are
presented in Table IV-2 , and indicate that BuAdATP inhibited
pol a with a potency more than four orders of magnitude
greater than that with which it inhibited pol The base
form of BuAdATP , BuA, and its 6-substituted derivative
BuAOMe (2- (p-n-butylanilino) -6-methoxypurine, Figure III-I),
were weaker inhibitors of both enzymes than was BuAdATP
, and
both base analogs displayed significant selectivity for pol
a compared to pol S (Table IV-I). The ATP isomer araATP (9-
arabinofuranosyl) adenine 5' 
-triphosphate, Figure IV-I)
inhibited both enzymes without significant selectivity
(Table IV-I).
The adenine analog, DCAA, and all of the DCAA
derivatives , inhibited pol a with greater potency than pol 
(Table IV-I). Table IV-2 presents the Ki values for
DCAdATP; pol a is inhibited by DCAdATP with a Ki value of 
, while the corresponding value for pol S is 66 ~M. Thus
the pol a selectivity of DCAdATP
, a close structural analog
of BuAdATP, is more than three orders of magnitude less than
that of BuAdATP. The latter observation suggests that there
II II 
\;O r-O-r-O-
OH 4Na
araA TP
: I
r5 
\,o r-o-r-o-
OH 4Na
araCTP
Figure IV-I. Structures of araATP and araCTP.
Table IV-2. potencies of Selected Inhibitors of DNA
polyrerases Alpha and Delta Assayed on
Activated DNA
Ki (~M) 2
Inhibitor pol a pol 
BuPdGTP 005
BuAdATP 005 150
DCAdATP
ddTTP
1Enzyre activities (pol a and HAP-5) were assayed under
the conditions described in Chapter II for activated DNA as
the template: primer. Assay mixes were truncated with
respect to the dNTP expected to be competitive with each
inhibitor .
2Ki values were determined on the basis of inhibitor
concentration enzyme activity curves (wright & Brown,
1976).
is considerable potential for the development of selective
inhibitors of pol 5 based on the DCAdATP motif; this
potential is discussed in Chapter VI.
dGTP analo None of the dGTP analogs tested displayed
selectivity for pol 5 compared to pol a (Table IV-I).
BuPdGTP , the dGTP analog of BuAdATP , appeared only weakly
selective for pol a compared to pol S when tested at 100 ~M.
However , like BuAdATP, this observation strongly understates
the selectivity of BuPdGTP for pol a; the Ki values of
BuPdGTP for pol a and pol S , presented in Table IV-2,
indicated that, like BuAdATP , BuPdGTP inhibited pol a with a
potency several orders of magnitude greater than that of pol
Three other N substituted dGTP analogs , EMPdGTP (N - (3-
ethyl-4-methylphenyl) -2' 
-deoxyguanosine 5' 
-triphosphate,
Figure IV-2), PhdGTP (N2- (phenyl) -2' -deoxyguanosine 5'-
triphosphate, Figure IV-2) and HexdGTP (N2- (n-hexyl) -2 '-
deoxyguanosine 5 I -triphosphate , Figure IV-2) were tested;
all three displayed inhibitory selectivity for pol a
compared to pol 5, and all were considerably weaker
inhibitors of both enzymes than was BuPdGTP (Table IV-I).
ACGTP (9- ( (2-hydroxyethoxy) methyl) guanine triphosphate,
Figure IV-2), the triphosphate analog of the antiviral agent
acyclovir and likely one of the active metabolites of that
agent in vivo (Elion et al., 1977), did not display
significant inhibitory selectivity for either enzyme (Table
I N
U-O-U-O-O. O. 
4HN+ (EtbOH 
EMPdGTP (R = 
-( )
Me )
PhdGTP (R = 
-( )
HexdGTP (R = 
-(CH2)SCH3 )
HN II II HN O-p-O-P-O-P-O-O. 0- 
4Na
ACVTP
Figure IV-2. Structures of EMPdGTP, PhdGTP,
HexdGTP and ACVTP.
IV-I) . It is important to note that if pol S is involved in
DNA metabolism in mammalian cells inhibition, of that enzyme
as well as others such as pol a by agents such as acyclovir
and AZT (see below) and their metabolites is a potential
contributor to their in vivo toxicity.
dCTP analo The arabinofuranosyl derivative araCTP
(9- ( arabinofuranosyl) cytidine 5' -triphosphate , Figure
IV-l), a CTP isomer, was an ineffective inhibitor of
truncated (-dCTP) DNA synthesis catalyzed by pol a
, while it
inhibited the analogous reaction catalyzed by pol 5 by 60%
(Table IV-I). Most of this apparent selectivity disappeared
with the addition of dCTP to the reaction mix; in the full
assay, pol a and pol S were inhibited by 40 and 71%,
respectively (Table IV-I). The observation that DNA
synthesis catalyzed by calf thymus pol a in the absence of
dCTP was resistant to inhibition by araCTP is in accord with
that of Yoshida et al. (1977), who also used pol a derived
from calf thymus. However , it is not consistent with
several observations that
, as an inhibitor of pol a derived
from a variety of sources
, araCTP displayed simple
competitive kinetics with respect to dCTP concentration (for
a review, see Cozzarelli
, 1977). Further , I have observed
that 100 ~M araCTP inhibits pol a derived from CHO cells 64%
when assayed under truncated (-dCTP) conditions. 1 It is
1 Resul ts not shown.
possible that sensitivity of pol a to inhibition by araCTP
in the absence of dCTP is a function of the source of the
enzyme. My observations suggest that, with calf thymus as
the enzYme source and truncated (-dCTP) polymerase reaction
conditions , araCTP could be used to inhibit selectively pol
5 and thereby distinguish it from pol 
hidicolin analo I measured inhibition of pol a and
pol 5 by aphidicolin and its derivatives in reaction mixes
lacking dCTP, because inhibition of pol a by aphidicolin is
competitive with dCTP (Oguro et al., 1979; Pedrali-Noy &
Spadari , 1979). The aphidicolin derivatives tested were 17-
acetylaphidicolin , 17, 18-diacetylaphidicolin, "16-
ketoaphidicolin" (3, 18-dihydroxy-17-noraphidicolan-16-one)
and 3-epiaphidicolin (Figure IV-3); each was synthesized in
the lab of Dr. George Wright by Dr. Lili Arabshahi as
described (Arabshahi et al., 1988), by the methods of
Dalziel et al. (1973). Aphidicol in was a potent inhibitor
of both pol a and pol 5 (Table IV-I), and , in agreement with
previously reported results (Goscin & Byrnes , 1982) the
compound did not display selective inhibition of either
enzyme. Each of the four derivatives of aphidicolin tested
(Table IV-I) inhibited both pol a and pol 5 with less
potency than the parent compound, and none displayed
significant selectivity for either enzyme.
dTTP analo Nei ther of the dTTP analogs tested
HO"
HO"
Figure IV-3.
Aphldlcolln (R = R' = H)
17-Acetylaphldlcolln (R = Ac, R' = H)
17,18-Dlacetylaphldlcolln (R = R' = Ac)
Eplaphldlcolln
16-Ketoaphldlcolln
Structures of Aphidicolin and
Aphidicolin derivatives.
displayed inhibitory selectivity for pol a or pol S (Table
IV -1) . AZTTP ((3' - azido) -2' -deoxythymidine 5' -triphosphate
Figure IV-4), the 5' -triphosphate derivative of the human
immunodeficiency virus inhibitor AZT, and likely its active
metabolite in vivo (Mitsuya et al., 1985), was a weak
inhibitor of both pol a and pol 5, and displayed selectivity
for neither enzyme (Table IV-I). 2' , 3' -Dideoxythymidine 5'
triphosphate (ddTTP, Figure IV-4) displayed similar potency
as an inhibitor of pol a and pol 5 (Table IV-l). However
the Ki values of ddTTP, 60 and 25 ~M for pol a and pol 5
respectively (Table IV-2), indicate that ddTTP displays some
inhibi tory selecti vi ty for pol 5 compared with pol a , an
observation in accord with the results of Wahl et ale
(1986) . At least one attempt has been made to exploit the
modest inhibitory selectivity of ddTTP for pol S compared to
pol a to determine a role for pol 5 in DNA metabolism 
vivo (Dresler & Kimbro, 1987).
hos hate analo I tested the inhibitory activity
of pyrophosphate (PPi, Figure IV-S) and two PPi analogs in
full assays rather than in truncated assays because the
structure of PPi did not suggest that it or its analogs
would be competi ti ve with any particular dNTP.
Phosphonoformate (PFA, Figure IV-S) (Reno et aI, 1978) was a
weak inhibitor of both pol a and pol 5, and did not display
selectivity for either enzYme (Table IV-I). The potency of
CH3
-O- -O- -O.O. O. 
4Na
AZTTP
O-P-O-P-O-P-OoO. O. 
ddTTP 4Na
Figure IV-4. Structures of AZTTP and ddTTP.
II O-p-O-P-O'O. O. 4Na
II R' O-p-C-p-O.
o. 4Na
O-P-R"
Figure IV-5.
PP,
MDP (R = R' = H)
F2MDP (R = R' = F)
PFA (R = COOH)
PAA (R" = CH2COOH)
Structures of PPi' MDP, F2MDP, PFA and PAA.
inhibi tion of pol a by PFA that I observed is less than that
observed by others (for a review, see oberg 1989), and it is
significantly less than I observed when assaying pol a and
pol S using poly(A) :oligo(dT) as the template:primer (see
section IV-D below). PPi and its isostere
difluoromethanediphosphonate (F2MDP , Figure IV-S) were also
weak inhibitors of both enzymes, but each inhibited pol 
selectively compared to pol a (Table IV-I). The latter
observation prompted me to investigate the inhibition of pol
a and pol S by PPi and F2MDP in greater detail.
Concentration vs. enzyme activity curves , determined by
Naseema Khan, (Figure IV-6) showed that F2MDP inhibited pol
S with an ICSO value of 0. 75 ro, while the compound was
ineffective as an inhibitor of pol a at concentrations up to
2 ro (Figure IV-6A). Analogous experiments with PPi (Figure
IV-6B) showed that that compound was a more potent inhibitor
of pol S than was F2MDP (ICSO = 0. 15 ro), but was less
selective relative to pol a , inhibiting the latter enzyme
with an ICso value of 0. 6 ro. The observation of the
selectivity of F2MDP for pol S compared to pol a prompted me
to investigate its mechanism of inhibition of pol a and pol
, and to survey the inhibitory potencies of the members of
a larger series of PPi analogs , with the goal of finding a
compound with improved potency and selectivity for pol 
The results of both sets of experiments are described below.
Figure IV-6.
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Figure IV-G. Concentration vs. enzyme activity curves
for inhibition of pol a and pol S by PPi and F2MDP.
activities (pol a and HAP-5) were assayed under the
Enzyme
conditions described in Chapter II, for poly (dA) : oligo (dT)
as the template: primer. (A) Inhibition of pol a and pol 
by F2MDP. (B) Inhibition of pol a and pol S by PPi.
D. Pyrophosphate and Difluoromethanediphosphonate:
Selective Inhibitors of DNA Polymerase Delta.
DNA ol erase assa conditions. As DNA polymerase
inhibitors , neither PPi nor its structural analogs were
expected to be competitive with any particular dNTP
, and,
therefore , the use of truncated assays with activated DNA
offered no advantage for measuring inhibition of pol 
activity. I therefore chose the template:primer preferred
by pol 5, poly(dA) :oligo(dT) (Focher et al. , 1988c) for the
investigation of the mechanism of inhibition of pol 5 by PPi
and its analogs , and for further screening of PPi analogs
(described below). I found that poly (dA) : oligo (dT) also is
an effective template:primer for pol a
, directing a level of
synthesis comparable to that directed by activated DNA. GMP
was included in all assays at a concentration of 2 
ro, to
inhibit the 3' ~ 5' exonuclease of pol 5 (Byrnes et al.
1977) and thereby keep the polymerase reaction linear with
time during the reaction period, even at the low dNTP
concentrations used in some experiments.
Inhibition of DNA merases al ha and delta b PPi and
i analo s usin
g p
:oli as the tem late: rimer.
I determined the ICSO values for PPi and four PPi analogs on
pol a and pol S; the results are presented in Table IV-3.
Both PPi, with ICSO values of 1 ro and 250 ~M for pol a and
pol 5, respectively, and F2MDP , with IC50 values of 10 ro
and 4 ro for pol a and pol 5 , respectively (Table IV-3),
were weaker inhibitors of both enzymes when assayed using
poly (dA) : 01 igo (dT) as the template: primer than they were
when activated DNA was used (see above). The degree of
selectivity of both compounds was not significantly altered
by the change in template: primer. Methanediphosphonate
(MDP, Figure IV-S), however , displayed steep concentration
vs. enzyme activity curves as an inhibitor of both pol a and
pol 5; neither enzyme was inhibited significantly by MDP at
3 ro, and both enzymes were inhibited almost completely at
10 ro. The phosphonates PFA and phosphonoacetate (PAA
Figure IV-S) (Leinbach et al., 1976) inhibited both enzymes
with greater potency than the other PPi analogs (Table IV-
3), but neither displayed inhibitory selectivity for either
enzyme.
Possible role of M 2+ chelation in the mechanism of
inhibition of DNA erase delta b PPi 2MDP and MDP.
The standard conditions which I used for the assay of pol 
included Mg2+ at 10 ro (Focher et al. , 1989). Because the
ICSO values of PPi, F2MDP and MDP as inhibitors of pol 
were wi thin an order of magnitude of the Mg2+ concentration,
I was concerned that one or more of the compounds inhibited
pol S primarily as a result of Mg2+ chelation. I tested
that possibility by measuring the potencies of the
inhibitors as a function of Mg2+ concentration. I first
Table IV-3. Potencies of PPi and Selected PPi Analogs asInhibi tors of DNA polYmerases Alpha and Delta
Assayed on Poly(dA) :oligo(dT) 
IC50 (ro) 
Inhibi tor pol a pol 
PPi
MDP
MDp
PFA
PAA
.:10
007
007
.:10
007
007
1Enzyme activities (pol a and HAP-5) were assayed under
the conditions described in Chapter II for activated DNA as
the template:primer.
2ICsO values were determined on the basis of inhibitor
concentration vs. enzyme activity curves of at least fivepoints.
3This compound displayed an unusually steep inhibitor
concentration vs. enzyme activity curve; see text, Chapter
, section 
measured the activity of pol 5 as a function of Mg
concentration. I found, in rough agreement with the
observations of Focher et ale (1989) that pol 5 displayed a
broad Mg2+ optimum centered at about 5 ro (Figure IV-7).
Next, I measured inhibition of pol 5 by PPi, F2MDP and MDP
as a function of Mg2+ concentration, and found that with
each compound, the degree of inhibition decreased with
increasing Mg2+ concentration (Table IV-4). MDP, an
inhibitor which displayed no selectivity for pol a or pol 
(Table IV-3), and an ICsO value for pol 5 close to the Mg
concentration used in most experiments (10 ro), may inhibit
pol 5 at least partially as a result of Mg2+ chelation.
Consistent with the hypothesis that MDP sequesters a
significant fraction of the Mg2+ in the assay mixes is the
observation that 3 ro MDP reversed inhibition of pol 
activity caused by high Mg2+ concentration, giving an
apparent 81% stimulation of pol S activity when the enzyme
was assayed in the presence of 15 ro Mg2+ (Table IV-4; see
also Figure IV-7). PPi and F2MDP inhibited pol 5 with IC50
values of 0. 25 and 4 ro, respectively; concentrations which
are below the concentration of Mg2+ in pol S assay mixes.
Since the data of Figure IV-7 indicates that 10 ro Mg2+ is
two to three times the optimum of that ion for pol 5, it
seems unlikely that that either PPi or F2MDP chelates enough
2+ at inhibitor concentrations near their IC50 values to
1 0
(Mg J (mM)
Figure IV-2. Activity of DNA polymerase delta as a
function of Mg2+ concentration.
the conditions described in Chapter I I, for
HA-delta was assayed under
poly (dA) oligo (dT) as the template :primer, except that the
2+ concentration was varied as indicated.
Table IV-4. Inhibition of DNA polYmerase Delta by PPi,
F2MDP and MDP as a function of Mg
Concentration 1
% Inhibition
(Mg ), ro:
Inhibitor (conc.
PPi (300 ~M)
F2MDP (3 ro)
MDP (3 ro) (33) (81)
1pol 5 (HAP-5) was assayed under the conditions
described in Chapter II, for poly(dA) :oligo(dT) as the
template: primer.
2Numbers represent percent inhibition of enzYme activity
by inhibitors present at indicated concentrations relative
to control activity, which was measured at the same Mg
concentration. Numbers in parentheses indicate percent
stimulation relative to controls.
inhibit pol S activity. Indeed , the data of Figure IV-7
indicate that sequestration of up to 70% of the free Mg2+ in
the assay mixes would have no effect on the acti vi ty of pol
2+ chelation might account for the increased potency
of PPi and F2MDP at Mg2+ concentrations below 10 ro (Table
IV-4) .
Patterns of inhibition of DNA polymerase delta by PP
MDP and PFA. To gain insight into the mechanism of
inhibition of pol 5 by the weakly selective inhibitor F2MDP
I examined the nature of its inhibitory effect on that
enzyme as a function of dTTP and poly(dA) :oligo(dT)
concentrations. For comparison, I performed analogous
experiments using PPi and the more potent but nonselective
analog PFA.
Analysis of PP action. The data summarized by the
Lineweaver-Burk plots of Figure IV-8 show that inhibition of
pol S by PPi is competitive with both dTTP and
poly (dA) oligo (dT) From the data of Figure IV-8A, I
calculated a Ki value for PPi of 540 t 250 ~M (the method of
calculation for this and analogous experiments described
below is detailed in Chapter II). The patterns of
inhibition are consistent with a mechanism in which PPi
binds the enzyme at a site which overlaps the site(s) of
both dTTP and poly(dA) :oligo(dT) binding; occupancy of this
si te interferes with the binding of both substrates
, and
Figure IV-8.
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Figure IV-8. Lineweaver-Burk analysis of inhibition of DNA
polymerase delta by PPi as a function of dTTP and
poly (dA) oligo (dT) concentrations. HAP-5 was assayed under
the conditions described in Chapter II , for
poly(dA) :oligo(dT) as the template:primer , except that dTTP
and poly(dA) :oligo(dT) concentrations were varied as
indicated. (A) dTTP as the variable substrate. (B)
Poly(dA) :oligo(dT) as the variable substrate.
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therefore is subj ect to competition by either.
Alternatively, the PPi binding site may be distinct from
those of one or both substrates
, and the binding of PPi and
the substrates may be mutually exclusive by an allosteric
mechanism.
Anal sis of F2MDP action. Lineweaver-Burk plots analogous
to those described above
, but using F2MDP as the inhibitor
show that this compound
, like PPi, was competitive with
dTTP (Figure IV-9A). However , unlike PPi, F2MDP was
noncompetitive with poly (dA) : oligo (dT) (Figure IV-9B). The
observed patterns of inhibition of pol S with respect to the
two substrates suggest that F2MDP binds a site on pol 
which overlaps the dNTP site but not the template:primer
site. As a result , F2MDP and dTTP compete for binding, but
the inhibitor and poly (dA) : oligo (dT) bind without effect on
one another. F2MDP might bind the allosteric site proposed
above, but if so, it fails to induce the PPi -specific
conformational change that results in competitive inhibition
with respect to template: primer. Alternatively, F2MDP may
not bind the same site as PPi, but a unique one
, independent
of the template:primer binding site but overlapping the dNTP
si te. From the data of Figure IV-9A I calculated a Ki value
for F2MDP of 1. 0 f 0. 2 ro.
Anal sis of PFA action. Lineweaver-Burk plots analogous to
those described above , but using PFA as the inhibitor
, show
Figure IV-9. 101
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Figure IV-9. Lineweaver-Burk analysis of inhibition of
DNA polymerase delta by F2MDP as a function of dTTP and
poly(dA) :oligo(dT) concentrations. HAP-5 was assayed under
the conditions described in Chapter II
, for
poly(dA) :oligo(dT) as the template: primer, except that dTTP
and poly (dA) : oligo (dT) concentrations were varied as
indicated. (A) dTTP as the variable substrate. (B)
Poly(dA) :oligo(dT) as the variable substrate.
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that this compound inhibits pol 5 uncompetitively with both
dTTP and poly(dA) :oligo(dT) (Figure IV-10, panels A and B).
The results are in accord with previous observations (for a
review, see oberg, 1989) which indicate that PFA inhibits
viral DNA polymerases and pol a derived from HeLa cells
uncompetitively or noncompetitively with respect to both
dNTP and template: primer concentrations. My observations
suggest that the binding site of PFA on pol 5 , unlike those
(or that) of PPi and F2MDP, is optimized or perhaps created
by the binding of the substrates. I calculated a Ki value
from the data of Figure IV-lOA of 9. 5 f 3 ~M.
Promise of PPi and F2MDP as robes of the function of
DNA erase delta. Neither PPi nor F2MDP was suitable as
an in vivo probe of the function(s) of pol PPi did not
inhibit pol 5 with sufficient selectivity compared to pol a
and it had the inherent disadvantage of susceptibility to
hydrolysis by phosphatases. F2MDP, although a more
selective inhibitor of pol 5 than PPi, was still not
selective enough to clearly discriminate the functions of
pol 5 and pol a in vivo In addition, F2MDP was such a weak
inhibitor of pol 5 that at concentrations expected to
significantly inhibit the latter enzyme, it may act
indiscriminately on important cell targets other than pol 
The inhibitory properties of PPi and F2MDP did indicate,
however, that the latter compounds represented a promising
Figure IV-10.
1.5
1.0
-0 0.
-0 -
g 4.
" 3.
104
(PFAJ. J.M: o 0
. 5
A 20
6 - 4 - 2 0.0 0.
1 / (dTTPJ (J.M)
(PFAJ. J.M: o 0
. 5
A 20
2 - 1 0.0 0.1 0.
1 / (poly(dA):oligo(dT)J (J.g mL -
105
Figure IV-10. Lineweaver-Burk analysis of inhibition of
DNA polymerase delta by PFA as a function of dTTP and
poly (dA) : oligo (dT) concentrations. HAP-S was assayed under
the conditions described in Chapter II
, for
poly(dA) :oligo(dT) as the template:primer
, except that dTTP
and poly(dA) :oligo(dT) concentrations were varied as
indicated. (A) dTTP as the variable substrate. (B)
Poly (dA) : oligo (dT) as the variable substrate.
106
structural basis for the development of a more ideal
inhibi tor of pol In the work described below, I
continued the search for a selective inhibitor of pol 
screening a new series of PPi analogs for inhibition of pol
a and pol 
E. Carbonyldiphosphonate: A Selective Inhibitor of DNA
polymerase Delta
Enz es and assa conditions. The experiments with pol
5 described in the previous sections were performed with
HAP-S (see section IV-B). During the course of the
experiments described below, a second, highly purified
preparation of pol S, called FPLC-5, became available 
(see
section IV-B). In the experiments described below, the
former preparation was used for inhibitor screening, and the
latter for the subsequent analysis of the mechanism of
inhibition of pol S by COMDP. In the cases where I tested
the potencies of inhibitors with both HAP-5 and FPLC-5, I
did not find a significant difference between the two;
therefore, comparison of results obtained with the two
enzymes seems warranted. Whenever possible,
poly (dA) :oligo(dT) was used as the template:primer in assays
of pol a and pol 5 activities.
screenin of a lar er set of PPi analo s for inhibition
of DNA erases al ha and delta. The observation that
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PPi and F2MDP inhibited pol S weakly, but selectively
relative to pol a
, suggested that other PPi analogs might
inhibit pol S with greater potency and greater selectivity
wi th respect to pol a. Numerous PPi analogs have been
synthesized because of their potential as antiviral agents
(Oberg, 1989). I obtained a series of PPi analogs
specifically MDP and PAA analogs
, from Dr. Charles McKenna
(University of Southern California); the structures and
acronyms of the latter compounds are given in Figure 
IV-II.
I tested the PPi analogs shown in Figure IV-II as inhibitors
of pol a and pol S
, and the results are summarized in Table
IV-S. The most potent inhibitors were the monohalogenated
PAA analogs FPAA, BrPAA and CIPAA
, none of which displayed
significant inhibitory selectivity for either pol a or pol
Two MDP analogs
, COMDP and FBrMDP
, displayed significant
selectivity for pol S
, the former with a potency as an
inhibitor of pol S (but not pol a) close to the potencies of
the monohalogenated PAA analogs on either 
enzyme.
Potencies of selected PPi analo
s as inhibitors of DNA
erases al ha activated DNA.
order to test the template: primer dependencies of the
inhibi tory potencies of ceratin PPi analogs
, I measured
inhibition of pol a and pol 5 using activated DNA rather
than poly(dA) :oligo(dT) as the template:primer. The
compounds tested were the five most potent inhibitors of 
pol
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II O-p-C-COOH II II O-p-C-p-O.O. 
COPM COMDP
II O-p-C-COOH II O-p-C-p-O.O. 
FPAA FBrMDP
BrP AA FMP
ClPAA MDP
PAA FClMP
FBrPAA ClBrMDP
FClPAA
CIMDP
CIBrPAA
MDP
Br2PAA
BrMDP
Br2MDP
FPPA
ClPP A
BrPPA
Figure IV-l1. Structures and acronyms of analogs ofPM and MDP.
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Table IV-S. Potencies of an Expanded Set of PPi Analogs asInhibi tors of DNA Polymerases Alpha and DeltaAssayed on Poly (dA) : oligo (dT) 
ICSO (~M) 2
Inhibi tor pol a pol 
FPAA
BrPAA
CIPAA
COMDP
COPAA
F2PAA
FBrMDP
FBrPAA
FCIPAA
FMDP
FCIMDP
C12PAA
CIBrPAA
Br2PAA
CIBrMDP
FPPA
CIPPA
BrPPA
CIMDP
C12MDP
BrMDP
Br2MDP
Dicyclohexylamine
Pyridine
1.2
300
::2000
1000
2000
1000
1000
2000
2000
2000
2000
;:2000
200
400
900
900
1000
2000
2000
2000
2000
2000
;:2000
;:2000
;:2000
;:2000
;:2000
;:2000
;:2000
Enzyme activities (pol a and HAP-S) were assayed under
the conditions described in Chapter II for
poly(dA) :oligo(dT) as the template:primer.
ICso values were determined on the basis of inhibitor
concentration vs. enzyme activity curves of up to 8 pointsdepending on the potency of each compound. I = inactive at2 ro, the highest concentration tested.
Dicyclohexylamine and pyridine were the bases forming
the counterions of several inhibitors
, and had no inhibitory
effect at 5 ro on either enzyme.
110
a and pol 5 assayed using poly(dA) :oligo(dT) as the
template:primer (Table IV-5). The results are summarized in
Table IV-6. Activated DNA-directed DNA synthesis catalyzed
by either enzyme was less sensitive to inhibition by each of
the compounds than was poly (dA) : 01 igo (dT) -directed synthesis
(compare the data of Tables IV-S and IV-6). Further, with
activated DNA as the template: primer, all five compounds
inhibi ted pol 5 with greater potency than pol a. Because of
its unique combination of potency and selectivity for pol 
compared to pol a, as well as the template:primer-
independence of that selectivity, I chose to study the
properties of COMDP as an inhibitor of poly (dA) : oligo (dT)-
directed DNA synthesis in greater detail.
Patterns of inhibition of DNA erases al ha and
del ta COMDP. Lineweaver-Burk analyses of inhibition of
pol a and pol 5 (FPLC-5; see above) assayed on
poly(dA) :oligo(dT) by COMDP, as a function of dTTP
concentration, are presented in Figure IV-12, panels A and
B, respectively. The results indicated that, with respect
to dTTP, COMDP inhibited pol a uncompeti ti vely and pol 
competitively . From the data of Figure IV-12, I calculated
Ki values for COMDP of 40 f 5 and 1. 8 f O. 3 ~M for pol a and
pol 5, respectively. Experiments analogous to those of
Figure IV-12 were performed, in which the concentration of
poly(dA) :oligo(dT) rather than dTTP was varied; Lineweaver-
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Table IV-6. Potencies of Selected PPi Analogs as Inhibitors
of DNA POlymerases Alpha and Delta Assayed on
Activated DNA 
IC50 (~M) 2
Inhibi tor pol a pol 
FPAA
BrPAA
CIPAA
COMDP
COPAA
160
120
300
170
Enzyme acti vi ties (pol a and HAP-S) were assayed under
the conditions described in Chapter II for activated DNA as
the template:primer.
ICSO values were determined on the basis of inhibitor
concentration vs. enzyme activity curves of 5 to 7 points.
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Burk analyses of the resulting data are presented in Figure
IV-13. The patterns of inhibition indicated that COMDP
inhibited both pol a and pol & in a mixed noncompetitive /
uncompetitive mode with respect to poly(dA):oligo(dT).
Clearly, lnhibition of neither enzYme was competitive with
poly(dA) :oligo(dT).
The observation that COMDP bound pol 5 competitively
with dTTP suggests that it bound part of the dNTP binding
site (this suggestion was further supported by results
described below, which indicated that COMDP is competitive
only with the dNTP specified by the template in the
polYmerase reaction). The similarity between the structure
of COMDP and the triphosphate group of a dNTP suggested
further that its binding site either overlaps or is
identical with the region of the dNTP site that binds the
triphosphate group of dNTPs. The observation that COMDP
binds pol a uncompetitively with dTTP suggests that, because
the dNTP site is occupied by dNTP when COMDP binds (the
definition of uncompetitive binding), the COMDP binding site
on pol a must necessarily be different from that of dNTP.
COMDP com etes onl with the dNTP s ecified b the
tem late. I performed experiments designed to determine
whether competitive binding of pol 5 between COMDP and dTTP
was specific to dTTP, was not specific (that is, whether it
would be competitive with any dNTP), or whether COMDP
Figure IV-12. 113
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Figure IV-12. Lineweaver-Burk analysis of inhibition of
DNA polyrerases alpha and delta by COMDP as a function of
dTTP concentration. FPLC-5 and pol 5 were assayed under the
conditions described in Chapter II, for poly (dA) : oligo (dT)
as the template: primer, except that the dTTP concentration
was varied as indicated. (A) Inhibition of pol a. (B)
Inhibition of pol 
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Figure IV-13. Lineweaver-Burk analysis of inhibition of
DNA polyrerases alpha and delta by COMDP as a function of
poly(dA) :oligo(dT) concentration. FPLC-5 and pol S were
assayed under the conditions described in Chapter II, for
poly(dA) :oligo(dT) as the template: primer, except that the
poly(dA) :oligo(dT) concentration was varied as indicated.
(A) Inhibition of pol (B) Inhibition of pol 
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competes only with the dNTP specified by the template.
poly(dA) :oligo(dT) as the template: primer, only dTTP
with
competed with COMDP; addition of a high concentration (800
~M) of dATP, dCTP or dGTP to the assay mix did not have a
significant effect on the potency of the inhibitor (Table
IV-7) . Poly (dC) : oligo (dG), when substituted for
poly(dA) :oligo(dT) as the template:primer, directed a level
of DNA synthesis by pol 5 about 20% of that directed by
poly (dA) oligo (dT) with poly(dC) :oligo(dG) as the
template: primer , the pattern of inhibition with respect to
varying dGTP concentration determined by Lineweaver-Burk
analysis (Figure IV-14) indicated that COMDP was competitive
with dGTP. From the data of Figure IV-14, I calculated a Ki
value for COMDP of 45 ~M, significantly higher than that
observed with poly(dA) :oligo(dT) as the template: primer.
Addition of 800 ~M dATP, dCTP or dTTP to the assay mix in
which poly(dC) :oligo(dG) was the template:primer had no
significant effect on DNA synthesis catalyzed by pol 
(Table IV-8). The latter observations support the
hypothesis that COMDP binds a site on pol 5 which is
occupied by the dNTP about to be incorporated onto the
growing primer chain during DNA synthesis.
COMDP is a readil reversible inhibitor of ol 
observed that COMDP gradually lost inhibitory activity when
stored at -20 . C in Tris buffer (a primary amine), whereas
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Table IV-7. Effect of dATP, dGTP and dCTP on Inhibition by
COMDP of DNA Polymerase Delta Assayed on
Poly (dA) : oligo (dT) 
% Inhibition
Control dATP dGTP dCTP
1pol 5 (FPLC-5) was assayed under the conditions
described in Chapter II, for poly(dA) :oligo(dT) as the
template: primer, with 800 ~M of a dNTP (or solvent control)
added as indicated.
Determined by comparing enzyme activity between samples
containing 800 ~M of the indicated dNTP (or solvent
control), with either 4 ~M COMDP or solvent control.
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Figure IV-14. Lineweaver-Burk analysis of inhibition
by COMDP of DNA polymerase delta assayed on
poly (dC) oligo (dG) as a function of dGTP concentration.
FPLC-delta was assayed as described in Chapter II, for
poly (dA) oligo (dT) as the template: primer, except that
poly (dC) : oligo (dG) was substituted for poly (dA) : oligo (dT)
and (3H)dGTP was substituted for (3H)dTTP.
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it was stable in HEPES buffer (a tertiary amine). The
latter observations and consideration of the structure of
COMDP suggested that its carbonyl group might bind pol S by
forming a Schiff base intermediate with a primary amine on
the surface of the enzyme. Such a reaction scheme is
depicted in Figure IV-IS. A Schiff base intermediate may be
stable, and thus may not readily dissociate. I tested the
latter possibility by performing the following experiment:
FPLC-S was incubated for up to 45 min at 37 o c with 8 ~M
COMDP (a concentration approximately four times its Ki for
pol 5; see above) in a polymerase reaction mix (( including
poly (dA) : 01 igo (dT)) lacking only dTTP. The inhibitor was
then separated from the enzyme by Sephadex G-2S
chromatography, and its activity and that of mock-treated
enzyme was measured. The results , which are summarized in
Table IV-9 , indicated that preincubation of pol 5 with COMDP
had no permanent effect on the enzyme activity. This result
is inconsistent with the notion that COMDP inhibited pol 
by forming a stable complex with it.
Treatment of a COMDP- ol S com lex with a reducin ent
results in irreversibl inactivated enz The results
described above did not eliminate the possibility that COMDP
formed a reversible Schiff base intermediate with a primary
amine on the surface of pol Such an intermediate might
be reducible, resulting in a covalent enzyme-inhibitor
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Table IV-8. Effect of dATP, dTTP and dCTP on Inhibition by
COMDP of DNA Polymerase Delta Assayed on
Poly(dA) :oligo(dT) 1
% Inhibi tion
Control dATP dTTP dCTP
pol 5 (FPLC-5) was assayed under the conditions
described in Chapter II, for poly(dA) :oligo(dT) as the
template:primer, except that poly(dC) :oli o(dG) was
substituted for poly(dA) :oligo(dT), and ( H)dGTP for
3HJdTTP, with 800 ~M of a dNTP (or solvent control) added
as indicated.
2Determined by comparing enzyme activity between samples
containing 800 ~M of the indicated dNTP (or solvent
control), with either 4 ~M COMDP or sol vent control.
NaBH4
-H2
NH2
Figure IV-IS. Schiff base formation between a
carbonyl group and a primary amine,
and its subsequent reduction by NaBH4.
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Table IV-9. Reversibility of Inhibition of DNA Polymerase
Delta by COMDp
H)dTMP Incorporation (pmoles)
Preincubation time (min) Control 8 ~M COMDP
12.
13.
10.
13.
13.
1pol S (FPLC-S) was assayed under the conditions
described in Chapter II, for poly(dA) :oligo(dT) as the
template: primer. The enzyme was pre incubated for the
indicated times with COMDP (or solvent). COMDP was then
separated from the enzyme by Sephadex chromatography,
H)dTTP was added , and enzyme activity was measured.
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complex (see Figure IV-15), perhaps thus in the vicinity of
the active site. I tested the latter possibility in an
experiment modeled after those of Basu and Modak (1987), in
which sodium borohydride (NaBH4) was used to effect
irreversible inactivation of coli DNA polymerase I with
pyridoxal phosphate. FPLC-5 was incubated at 37 . C with 8
~M COMDP in a reaction mix including poly (dA) : oligo (dT) and
lacking only dTTP. After 20 min, NaBH4 was added to a final
concentration of 5 ro. Incubation was continued for 10 min,
and the enzYme was separated from the inhibitor and reducing
agent by Sephadex G-25 chromatography. Enzyme activity was
then measured as described in Chapter II. Analogous samples
in which NaBH4' COMDP or both were omitted were included as
controls. The results, which are summarized in Table IV-
10, indicated that NaBH4 promoted COMDP-dependent
inactivation of pol In subsequent experiments , I found
that (i) when poly(dA) :oligo(dT) was omitted from the
preincubation mix, COMDP was still capable of irreversible
inhibition of pol 5 on treatment with NaBH4 (Table IV-II),
and (ii) the degree of COMDP-dependent inactivation after
NaBH4 treatment was not changed by the presence of 4 or 8 ~M
dTTP (Table IV-12). If irreversible inhibition were a
resul t of covalent binding to the dNTP site of pol 5, one
would expect an active template:primer to enhance it and
dTTP to decrease or prevent it. Therefore, observations (i)
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Table IV-10. Activity of DNA polymerase Delta by COMDP After
Treatment with COMDP and NaBH4
3H)dTMP Incorporation (picomoles)
NaBH4 (ro) Control 8 ~M COMDP
pol 5 (FPLC-5) was assayed under the conditions
described in Chapter II, for poly(dA) :oligo(dT) as the
template: primer. The enzYme was pre incubated with COMDP (or
solvent) for 20 min, then NaBH4 (or solvent) was added to a
final concentration of 5 ro, and incubation continued for 10
min. NaBH4 and COMDP were then separated from the enzyme by
Sephadex chromatography, ( H)dTTP was added, and enzyme
activity was measured.
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and (ii) suggest that irreversible inactivation of pol 5 by
COMDP is a result of covalent binding of the compound to a
site on the enzyme distinct from its active site.
Effect of COMDP on the 3' ~ 5' Exonuclease Activit
Pol 5. I assayed the 3' ~ 5' exonuclease activity of FPLC-S
by measuring its ability to catalyze excision of the primer
termini of the synthetic template: primers
poly(dA) :oligo(dT) 12-18 pJdC)0. 33 and
poly(dA) :oligo(dT) 12-18 3H)dT)0. 3. I prepared the
radiolabeled homopolymers as described in Chapter II.
Exonuclease activity measured on the mismatched primer
terminus was 15 to 20% that of polymerase activity measured
under standard conditions; with the properly base paired 3'-
OH terminus, it was only 2. 5 to 4% that of polymerase
activity. The ratio of the exonuclease activities that I
observed with matched and mismatched primer termini is
consistent with suggestions that the 3' ~ 5' exonuclease is
a "proofreading" exonuclease, which is an important
contributor to the DNA replication fidelity of pol 5 (Kunkel
et al., 1986). I found that COMDP inhibited the exonuclease
activity only weakly, displaying ICSO values determined on
the basis of concentration vs. enzyme activity curves
(Figure IV-16) which were greater than 1 ro with either
template: primer.
127
Table IV-II. Activity of DNA polYmerase Delta After
Treatment with COMDP and NaBH4 in the Presence
or Absence of Poly (dA) : oligo (dT) 
3H)dTMP Incorporation (picomoles)
(poly(dA) :oligo(dT))
(~G mL -1 ) 2
Control 8 ~M COMDP
1pol S (FPLC-5) was assayed under the conditions
described in Chapter II, for poly(dA) :oligo(dT) as the
template:primer. The enzyme was pre incubated with COMDP (or
solvent) for 20 min in the presence of the indicated
concentration of poly(dA) :oligo(dT), then NaBH4 (or solvent)
was added to a final concentration of 5 ro, and incubation
continued for 10 min. NaBH4 and COMDP were then separated
from the enzYme by Sephadex chromatography, ( 3H) dTTP and
poly(dA) :oligo(dT) were added, and enzYme activity was
measured.
2Indicates concentration in the preincubation mix.
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Table IV-12. Activity of DNA Polymerase Delta After
Treatment with COMDP and NaBH4 in the Presence
or Absence of dTTp
3H)dTMP Incorporation (picomoles)
(dTTP) (~M) 2 Control 8 ~M COMDP
1pol 5 (FPLC-5) was assayed under the conditions
described in Chapter II, for poly (dA) :oligo(dT) as the
template: primer, with the template: primer present. The
enzyme was pre incubated with COMDP (or solvent) for 20 min
in the presence of the indicated concentration of
(unlabeled) dTTP, then NaBH4 or solvent) was added to a
final concentration of 5 mM, and incubation continued for 
min. NaBH4' COMDP and dTTP were then separated from the
enzyme by Sephadex chromatography, ( 3H)dTTP was added, and
enzyme activity was measured.
2Indicates concentration of unlabelled dTTP in the
preincubation mix.
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100
0 Mismatched 3 terminus
Properly paired 3 terminus
200 400
(COMDPJ (J1M)
1000 2000
Figure IV-16. Concentration enzyme activity
curves for inhibition of the 3' to 5' exonuclease activity
of pol delta (FPLC-delta) by COMDP. The exonuclease
activity, using either a mismatched or a properly base
paired template :primer substrate was assayed as described in
Chapter I I 
CHAPTER V
INHIBITION OF PERMEABLE CELL DNA SYNTHESIS
A. Introduction
COMDP is an ineffective inhibitor of intact cell rowth
and macromolecule s nthesis. COMDP has a critical
shortcoming as a discriminator of the function of pol 
vivo ; it is charged , and therefore likely penetrates intact
cell membranes poorly if at all. Consistent with the notion
of poor membrane penetration is the observation of Stenberg
(1981) that 500 ~M COMDP did not inhibit mammalian cell
macromolecule synthesis. I measured CHO cell ( H) TdR
incorporation in the presence or absence of COMDP by the
technique described in Chapter II. CHO cells were incubated
at 37 o c for 3 h in the presence of 20 or 200 ~M COMDP
, or
i ts solvent as a control. H)TdR was added to each
incubation was continued for 30 min , and samples were
,..
prepared for scintillation counting as described in Chapter
II. I found that there was no significant difference in the
amount of ( 3H) TdR incorporation between control samples and
samples of cells treated with either concentration of COMDP.
I also measured the effects of COMDP on CHO cell growth in
monolayer culture. CHO cells were plated in a 24-well
tissue culture plate at a low density (5 to 10% confluence).
COMDP was added to some wells to a final concentration of
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200 ~M, and an equal volume of solvent was added to the
others. The cells were incubated at 37 . C, and observed
after 24, 48 and 72 At each time point, the cells
treated with COMDP were indistinguishable from mock-treated
cells, both in their appearance and in their density
(percent confluence). After 72 h, all of the cultures
regardless of the presence or absence of COMDP , had achieved
30 to 50% confluence. Both sets of observations confirm
those of Stenberg (1981) and support the notion that the
charge of COMDP 1 imi ts its use as a probe of the in vivo
function of pol 5 to measurement of its capacity to inhibit
macromolecule synthesis in isolated nuclei or in membrane
permeabilized cells. I measured the effect of COMDP on CHO
cell DNA synthesis in experiments of the latter type; the
resul ts are described below.
B. Effect of Inhibitors on Permeable Cell DNA Synthesis
Permeabilization of CHO cells. I used the technique of
Dresler et ale (1982), adapted for use with CHO cells , for
measurement of (a-32P)dATP incorporation into permeabilized
CHO cells. I effected CHO cell permeabilization by
incubating cells at 0 . C in a slightly hypotonic buffer, as
detailed in Chapter II. In the cases of HeLa cells (Seki et
1 S. L. Dresler, Washington University School of Medicine
unpublished.
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al. , 1975) and mouse L cells (Berger & Johnson , 1976), a
similar treatment caused cells to swell and release
proteins, but their cell membranes maintained their
integrity, and after permeabilization the cells incorporated
exogenous dNTPs and NTPs into DNA and RNA, respectively.
measured incorporation of (a-32pJ dATP by permeabilized cells
during an incubation at 37 o c of 8 min , which was within the
linear portion of the reaction. I estimated background
counts by the apparent incorporation of (a-32p)dATP in
samples of permeable cells which were not incubated at 37
o C. Samples incubated at 37 o c for 8 min in the presence of
200 ~M aphidicolin, a concentration expected to inhibit
replicative DNA synthesis in permeabilized cells almost
completely (Dresler, 1984), displayed insignificant (a-
32p)dATP incorporation above background. Since aphidicolin
selectively inhibits mammalian cell replicative DNA
synthesis, and not RNA, (repair) DNA or protein synthesis
(Huberman, 1981), the latter result indicated that the
incorporation above background measured in the absence of
inhibitors was due almost entirely to replicative DNA
synthesis.
In an attempt to maximize the degree of inhibition by
certain compounds , I changed the concentrations of the
unlabeled dNTPs (dCTP, dGTP and dTTP) in the incubation
mixtures from SO to 1 ~M (the dATP concentration was 1 ~M in
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all cases). COMDP inhibition was measured in this manner
because, based on its effects on pol S (Chapter IV, Figures
IV-12 and IV-14), the compound most likely inhibits pol 
competitively with all four dNTP substrates, and, thus,
minimizing the total dNTP concentration might have maximized
the degree of inhibition by COMDP. In the case of FPAA, I
did not know whether the compound would inhibit pol a or pol
5 competitively with any dNTP; if so , it seemed unlikely
that it would be competitive with any particular dNTP.
measured the potency of inhibition by aphidicolin at reduced
dNTP concentrations because that compound inhibited DNA
synthesis in vivo competitively with all four dNTPs (Ayusawa
et al., 1980). I found that the change in dNTP
concentration did not have a significant effect on the
amount of incorporation of (a-32P)dATP by the permeabilized
cells during the assay period.
potencies of selected com ounds as inhibitors of
ermeable cell DNA s nthesis. I tested the potencies of
several compounds as inhibitors of DNA synthesis in
permeabilized CHO cells, and the results are summarized in
Table V-I. Aphidicolin inhibited permeable cell DNA
synthesis with an ICSO value of O. 2 ~M, a potency about an
order of magnitude greater than that expected based on the
potency of the compound as an inhibitor of pol a and pol 
(Lee et al., 1985). FPAA inhibited permeable cell DNA
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Table V-I. Inhibition of ( 32p) dATP Incorporation into
Permeabilized CHO Cell DNA
Inhibi tor ICSO (~M) 2
Aphidicolin
FPAA
COMDp3 , 4
DCAA
BuAdATP
BuA
200
200
200
1 ( p) dATP incorporation into the DNA of permeabilized
CHO cells was measured as described in Chapter II. Cells
were made permeable , added to solutions containinginhibitors (or solvent control) and (a-32p)dATP , and
incubated at 37 oc for 8 min. Samples contained 7. 5 to 15 x
5 permeabilized cells, contained 2000 to 2500 cpm of
previously incorporated ( 3H) TdR, and typically incorporated
1500 to 3000 cpm (17 to 34 picomoles) of (a- p)dATP during
the assay period. Background counts were estimated as the
counts in samples not incubated at 37 o
2ICSO values were determined on the basis of inhibitor
concentration vs. percent activity curves. I = inactive at
200 ~M, the highest concentration tested.
Inhibi tion by aphidicol in, FPAA and COMDP was measured
as described in Chapter II , except that the unlabelled dNTPs
(dCTP, dGTP and dTTP) were present at 1 rather than SO ~M.
The change in dNTP concntrations had little effect onincorporation of ( 32p) dATP by permeabilized cells.
4COMDP displayed 50% inhibition of permeabilized cell
DNA synthesis at 200 ~M, the highest concentration tested.
The statement that 200 ~M is the ICSO value of COMDP as an
inhibitor of permeabilized cell DNA synthesis is based on
the assumption that 100% inhibition of permeabilized cell
DNA synthesis can be achieved at a higher COMDP
concentration.
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synthesis with a potency (ICSO = 6 ~M) about S-fold less
than that which it displayed for inhibition of pol a and pol
5 when assayed using poly (dA) : 01 igo (dT) as the
template:primer (Table IV-S), and at the (logarithmic)
midpoint of the values obtained in analogous experiments
employing activated DNA as the template:primer (Table IV-6).
BuA and DCAA were significantly weaker inhibitors of
permeable CHO cell DNA synthesis (being inactive, and
displaying an ICSO value 200 ~M, respectively; Table V-I)
than they were of either ( 32p)phosphate incorporation into
intact CHO cell DNA (IC50 values of 30 and 12 ~M,
respectively; Table 111-3), or of pol a assayed using
activated DNA and (-dATP) truncated conditions (71 and 67%
inhibition at 100 ~M; Table IV-I). BuAdATP inhibited
permeable cell DNA synthesis with an ICSO value 200 ~M;
Table V-I) greater than its Ki values as an inhibitor of pol
a or pol 5 (0. 005 and 150 ~M, respectively; Table IV-2).
is not clear why BuA, DCAA and BuAdATP were such weak
inhibitors of permeabilized cell DNA synthesis. In the case
of BuAdATP, the result is surprising, since both BuPdGTP
(Dresler & Frattini, 1986; 1988) and BuAdATp2 inhibited DNA
synthesis in permeabilized human fibroblasts with IC50
values of 3 ~M. It should, however, be noted that in
2 s. L. Dresler, Washington University School of Medicine
unpubl ished.
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estimating the ICsO values of weak inhibitors (those with
ICsO values 200 ~M, the highest concentration tested in
all cases), I assumed that 100% of the activity was
susceptible to inhibition. It is conceivable that pol a
catalyzes only one half of the total DNA synthesis in
permeabilized cells, and as a result, a selective pol a
inhibi tor may only be capable of inhibiting 50% of the total
activity. Thus, SO% of the maximum inhibition of
permeabilized cell DNA synthesis that a compound is capable
of may occur at inhibitor concentrations lower than the
values given in Table V-I.
COMDP inhibited permeable cell DNA synthesis with an
ICSO value of 200 ~M (Table V-I) . That value is
significantly higher than its Ki values as an inhibitor of
pol a and pol 5, assayed using poly (dA) : oligo (dT) as the
primer:template (40 and 1. 8 ~M, respectively; Chapter IV,
Figure IV-12), but between its ICSO values as an inhibitor
of pol a and pol 5 using activated DNA as the
template:primer (300 and 40 ~M, respectively; Table IV-6).
If, as mentioned above, 100% inhibition of permeabilized
cell DNA synthesis is not achievable at a higher COMDP
concentration, the ICSO of the compound may be closer to 40
~M, and may therefore reflect in vivo inhibition of pol 
Another possibility is that if the inhibitor concentration
vs. percent activity curve were extended to higher COMDP
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concentrations , the curve might indicate biphasic
inhibition, reflecting in vivo inhibition of pol S at lower
concentrations, and pol a at higher concentrations.
BuAdATP and COMDP do not inhibit ermeable cell DNA
nthesis s ner isticall I tested the possibility that
BuAdATP and COMDP, selective inhibitors of pol a and pol 
respectively (Chapter IV), inhibit permeabilized cell DNA
synthesis synergistically as a result of their combined
action on pol a and pol The hypothesis that simultaneous
inhibi tion of pol a and pol 5 results in increased potency
of inhibition of DNA synthesis is speculative , but is
supported by some observations. For example, aphidicolin, a
nonselective inhibitor of pol a and pol 5 (Goscin & Byrnes
1982; Lee et al., 1985) inhibited permeable cell DNA
synthesis with significantly greater potency than those with
which the compound inhibited pol a and pol 5 (see above).
measured permeable cell DNA synthesis in the presence or
absence of various concentrations of BuAdATP, COMDP or both,
at reduced concentrations of dNTPs (see above), and the
resul ts are summarized in Table V-2. The potency of BuAdATP
as an inhibitor of permeabilized cell DNA synthesis was not
changed by decreasing the concentrations of the unlabelled
dNTPs from SO to 1 ~M; the data of Table V-2 indicate that
the ICSO value of BuAdATP was still 200 ~M (Table V-I)
138
Table V-2. Inhibition of (32p)dATP Incorporation into
Permeabilized CHO Cell DNA by BuAdATP, COMDP and
combinations thereof1 
Inhibitor concentration (~M)
BuAdATP COMDP % Inhibition
200
200
100 100
32p)dATP incorporation into the DNA of permeabilized
CHO cells was measured as described in Chapter II, except
that the unlabelled dNTPs (dCTP , dGTP and dTTP) were present
at 1 rather than SO ~M. Cells were made permeable, added to
solutions containing inhibitors ( or solvent control) and
32p)dATP, and incubated at 37 'C for 8 min. Background
counts were estimated as the counts in samples not incubated
at 37 '
. i.
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under the conditions of reduced dNTP concentrations. The
degree of inhibition by BuAdATP and COMDP when present
together (Table V-2) was clearly no more than the sum of
their individual actions; no synergism between the two
inhibi tors was apparent.
Assuming the val idi ty of the hypothesis that
simultaneous inhibition of pol a and pol 5 should result in
synergistic inhibition of cellular DNA synthesis , there are
several possible reasons for the observed lack of synergism.
One derives from that postulated above for the weakness of
COMDP as an inhibitor of permeabilized cell DNA synthesis.
The potencies of inhibition of pol a and pol S are a
function of the composition of the template:primer, and,
further, a change in the template:primer does not
necessarily change the sensitivities of pol a and pol 
equally. Thus, COMDP might by template: primer effects alone
might not inhibit that enzyme selectively 
in vivo relative
to pol a. If so, synergistic inhibition of DNA synthesis by
BuAdATP and COMDP would not be expected.
( ; 
CHAPTER VI
DISCUSSION
A. Correlation of Inhibition of DNA Polymerases Alpha
and Delta and Cellular DNA synthesis
The present study represents progress toward the long
term goal of using selective inhibitors of pol 5 to probe
and define the role of that enzyme in mammalian cell
replicative DNA synthesis. I succeeded in finding a
compound (COMDP) which inhibited pol 5 selectively with
respect to pol a, and I characterized its action on pol 5 in
detail. However, the results of the limited experiments
that I performed using permeable cells and COMDP, in an
attempt to find evidence for the participation of pol 5 in
DNA replication, were inconclusive.
Inhibition of cellular DNA s nthesis b COMDP. COMDP
was a weak inhibitor of permeable cell DNA synthesis
displaying an ICSO value of 200 ~M. That value is
considerably higher than its Ki values as an inhibitor of
pol a (40 ~M; Figure IV-12) and pol 5 (1. 8 ~M; Figure IV-
12), using poly(dA) :oligo(dT) as the template:primer, but
between its ICSO values when the enzymes were assayed using
activated DNA as the template:primer (300 and 40 ~M,
respectively; Table IV-6). From these results, it is
difficult to draw conclusions about the role of pol 5 in the
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aphidicolin sensitive DNA synthesis in permeabilized cell
system. The most likely source of uncertainty is the
variation in the potency of COMDP as a function of the
composi tion of the template: primer used in the DNA
polymerase assay. In addition to the differences in COMDP
potencies when the enzymes were assayed using
poly(dA) :oligo(dT) vs. activated DNA , I found that when
poly(dC) :oligo(dG) was the template:primer (Figure IV-12),
the Ki value of COMDP for inhibition of pol 5 was 45 ~M
twenty-five times that observed when the template:primer was
poly (dA) : ol igo (dT) . The latter observation serves to point
out the difficulty in correlating the potency of inhibition
of pol S by a compound with the characteristics of the
template: primer used in the assay. Poly (dC) : oligo (dG)
presents a DNA polymerase enzyme with the same primer
density and the same long (compared with activated DNA)
stretches of single stranded DNA as does poly(dA) :oligo(dT),
yet the activity of pol 5 and its sensitivity to inhibition
by COMDP are significantly different between the two. It is
equally questionable to attempt to correlate the activity of
an enzyme on a particular template: primer with its
sensitivity to inhibition, since, for example, pol a is
equally active on poly(dA) :oligo(dT) and activated DNA, yet
is much less sensitive to inhibition by COMDP when it is
assayed using the latter (Ki = 40 vs. ICSO = 300 ~M,
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respectively) . Even if the relationship between the
characteristics of a template:primer and sensitivity to
inhibition were known, it would still be impossible to know
how well any particular template:primer combination
approximates the template:primer substrate that a
replicative DNA polymerase uses in vivo In addition to
template effects , one must consider that COMDP seems capable
of reversibly forming a Schiff base with primary amines
(Chapter IV). It is possible that in permeabilized cells
enough COMDP is in such a state that the concentration of
(free) COMDP is significantly less than would otherwise be
expected. The inhibitory potency in the permeabilized cell
assay of FPAA, which, like COMDP, is a charged pyrophosphate
analog, argues against the possibility that the replicative
enzymes in the nuclei of permeabilized cells are somehow
physically inaccessible to COMDP.
In view of the results and arguments presented above, it
is clear that pol 5-specific inhibitors with much greater
potency and selectivity than COMDP must be developed to be
of use in defining the role of pol 5 in replicative DNA
synthesis in vivo such a compound would not, however,
guarantee success. Even BuPdGTP, an inhibitor of pol a with
nanomolar range potency (Khan et al. , 1984) and three to
four orders of magnitude selectivity relative to pol S (Lee
et al., 1985; Table IV-2), inhibited permeable mammalian
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cell DNA synthesis with an ICSO value of 3 ~M (Dresler 
Frattini, 1986; 1988), and thus did not clearly indicate a
role for pol a in mammalian cell DNA synthesis.
B. Inhibition of DNA Polymerases by COMDP
COMDP inhibits DNA erases al ha and delta b
different mechanisms. The properties of COMDP as an
inhibitor of pol a and pol 5 are significant both because
the compound is the first known small molecule which
inhibits pol 5 with significantly greater potency than pol
a, and because the apparent mechanisms of inhibition of the
two enzymes by the compound are different. The results of
Lineweaver-Burk analyses (Chapter IV, Figures IV-12 and IV-
14) indicate that COMDP binds part of the dNTP binding site
of pol 5, whereas the same is not true in the case of pol a
(Figure IV-12). As described below, these properties of the
inhibitor carry important implications both for the
development of more potent inhibitors of pol & based on
COMDP, and also for the use of COMDP and COMDP derivatives
as probes of the structure and function of pol 
dNTP analo s of COMDP. Based on the observation that
COMDP inhibits pol 5 competitively with dNTPs, and in
consideration of the structure of the compound, I propose
that the compound binds pol & at the part of its active site
which binds the 5' -triphosphate group of the " incoming"
j' 
144
dNTP. If COMDP binds the dNTP site as a dNTP analog, then a
COMDP analog which more closely resembles a dNTP, for
example, a dNTP in which the 
phosphoanhydride oxygen is
replaced with a carbonyl group (Figure VI-I), might bind
that site with greater affinity than COMDP. Further, the
kinetic studies suggest that COMDP does not bind the
analogous site on pol a, and if so, a dNTP analog of COMDP
might not bind that site either. As a result, a dNTP analog
of COMDP might display greater inhibitory selectivity for
pol 5 compared to pol a than the parent compound COMDP.
Irreversible inhibition of DNA 
erase delta b COMDP
and COMDP derivatives. The observation that COMDP gradually
lost inhibitory potency in a buffer containing the primary
amine Tris, along with a consideration of the inhibitor
structure, suggested that COMDP might form a stable Schiff
base with a primary amine in the active site of pol 
attempt to reduce this hypothetical complex with NaBH4
caused irreversible inactivation of the enzyme; however,
subsequent experiments revealed that inactivation was not
dependent on the presence of poly (dA) : oligo (dT), and was not
prevented by excess dTTP. The latter observation suggested
that NaBH4 -dependent inactivation of pol S by COMDP was due
at least in part to Schiff base formation outside of the
active site of the enzyme. Thus, the experiments neither
demonstrated nor ruled out Schiff base formation by COMDP in
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Figure VI-l. Proposed dNTP analog of COMDP.
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the active site of pol dNTP analogs of COMDP such as
those proposed above might fail to form Schiff bases with
residues of pol 5 outside of its active site, and therefore
might serve as irreversible pol S active site labelling
reagents. The observation of Basu and Modak (1987) that
pyridoxal phosphate can be used to irreversibly label the
active site of coli DNA polYmerase I suggests that an
analogous derivative of COMDP, in which a group such as
pyridoxal is linked to it, might likewise serve as an
irreversible active site probe of pol 5 (Figure VI-2) 
COMDP as a robe of the structure of DNA 
ol erase
del ta . At least two conclusions can safely be drawn
concerning the structure of pol S based on studies with
COMDP. One is that the difference in potency and mechanism
of inhibition of pol 5 by the compound each argue that there
are at least some structural differences in the active site
regions of the two enzymes. The other is that, based on the
observation that the 3' ~ 5' exonuclease activity of pol 
is resistant to inhibition by COMDP, the 3' ~ 5' exonuclease
activity and DNA polymerase sites of pol 5 may be
structurally and functionally distinct. Freemont et al.
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Figure VI-2. Proposed pyridoxylated derivative
of COMDP.
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(1988) have demonstrated by X-ray crystallography that the
DNA polYmerase and 3' ~ S' exonuclease sites of the Klenow
fragment of col i DNA polymerase I are spaced about 15 A
apart; perhaps the same is true of pol 
Inhibi tion of other DNA ol erases b COMDP. COMDP is
a weak inhibitor of mammalian cell pol and pol The
compound is, however, a potent inhibitor of several viral
DNA polymerases , displaying ICSO values $ 10 ~M as an
inhibi tor of the DNA polymerases of Herpes Simplex Virus
Type 1 (Eriksson et al. , 1980), Human Cytomegalovirus
(Eriksson et al., 1982), Epstein-Barr Virus (Oberg, 1989)
and the reverse transcriptase of the Human Immunodeficiency
Virus (HIV) (Vrang & oberg, 1986). In the latter case, the
potency of inhibition was , as I observed in the case of pol
, strongly a function of the composition of the
template:primer used in the reaction; the compound inhibited
reverse transcriptase with ICSO values of 4 ~M when assayed
on poly(A) :oligo(dT), 110 ~M with poly(C) :oligo(dG) and 200
~M with poly(dC) :oligo(dG) (Vrang & oberg, 1986). COMDP
inhibited HIV reverse transcriptase in a mixed uncompetitive
/ noncompetitive mode with respect to dTTP concentration
when the enzyme was assayed using poly (A) : oligo (dT) (Vrang 
oberg, 1986), in contrast with my results in the cases of
pol a (uncompetitive) and pol 5 (competitive). The
1 C. E. McKenna, personal communication.
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observations that the potency of COMDP as an inhibitor of
pol S and of several viral polymerases raises an important
point made in Chapter IV in the context of the inhibitors
AZTTP and ACGTP; if pol 5 is involved in mammalian cell DNA
metabolism, then inhibition of that enzyme by putative
antiviral agents must not be overlooked as a potential
contributor to their cytotoxicity.
C. Future Directions
Develo ment of otent and selective inhibitors of DNA
ol erase delta based on COMDP. As a lead toward the
development of inhibitors of increased potency and
selectivity for pol S, the structure of COMDP suggests two
approaches. One, discussed above, is the development of
dNTP analogs of COMDP. The other is the development of
other PPi analogs. Because of their potential for clinical
use as antiviral agents , a large number of phosphate and PPi
analogs have been synthesized (Oberg, 1989). The simplicity
of the structures of PPi and COMDP, and a consideration of
the large number of their analogs in existence , suggests
that most or all of the COMDP analogs that one might imagine
as potential pol 5 inhibitors have already been synthesized.
The task remains to collect samples of a number of such
compounds and test their inhibitory potencies toward pol 
Develo ment of selective inhibitors of DNA erase
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del ta based on DCAdATP. As noted in Chapter IV, both
BuAdATP and DCAdATP are selective inhibitors of pol a
relative to pol 5; however, the selectivity of the latter
compound is more than three orders of magnitude less than
that of the former. That observation, along with a
consideration of the structural similarities and differences
between BuAdATP and DCAdATP, suggests a rational basis for
the development of other 2-substituted dATP analogs which
might display potent and selective inhibition of pol 
a first step, I would suggest that derivatives of the purine
base analog 2AA be synthesized in which the 3-position of
its anilino ring is substituted with a series of halogen and
alkyl groups, starting with chloro, bromo, methyl and ethyl
groups (Figure VI-3) . The compounds could be tested for
inhibition of pol a and pol 5 , and ones with promising
inhibitory properties could be derivatized to their 2'-
deoxyribonucleoside 5' -triphosphate forms for further
testing. Although this approach would be more difficult
than screening an expanded series of PPi analogs, it seems
to hold a greater potential for the discovery of an
extremely potent and selective inhibitor of pol S, analogous
to BuAdATP and BuPdGTP in the case of pol 
Use of selective inhibitors of DNA merase delta to
discern a role for that enz e in cellular DNA metabolism.
In the present study, I attempted to use COMDP to detect the
151
NH2
R = , Br, Me, Et.
Figure VI-3. Proposed 2AA analogs.
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participation of pol 5 in permeabilized cell replicative DNA
synthesis , and as described above , the results were
inconcl us i ve . Despite the potential pitfalls noted above
the technique of cell permeabilization seems to hold
considerable promise for the study of the cellular role of
pol 5, especially if compounds are developed which possess
sufficient potency and selectivity for pol S to diminish the
problem of the variability of inhibitor potency with
template:primer composition. A unique advantage of the
permeabilized cell assay compared to studies with intact
cells is that, with permeable cells, the dNTP concentration
can be varied at will. For example, the observation that a
compound with the properties of COMDP inhibited permeable
cell DNA synthesis competitively with dNTPs would constitute
good evidence that the compound inhibited permeable cell
synthesis by means of inhibition of pol 5 rather than pol a.
It seems unlikely that inhibitory mechanism is so strongly a
function of the template:primer composition as inhibitor
potency is.
A selective inhibitor of pol 5, perhaps COMDP itself,
might be used to test the hypothesis of Focher et ale
(1988a) and Downey et ale (1988) that pol a and pol 
catalyze lagging and leading strand synthesis, respectively.
For example, Dresler and Frattini have found that BuPdGTP
preferentially inhibited Okazaki fragment synthesis in
0!"
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permeabilized human fibroblasts. It remains to be shown
whether a selective pol 5 inhibitor such as COMDP
preferentially inhibits leading strand synthesis, which
would be indicated by a preference by the compound for
inhibi tion of synthesis of long DNA strands.
Role of DNA erase delta in re air s nthesis.
":'
have limited the present discussion to the controversial
. .
role of pol 5 in mammalian cell DNA replication. For
completeness , I wish to note that there is also evidence for
a role for pol 5 in certain types of mammalian cell DNA
repair synthesis (Dresler & Frattini, 1986; Dresler &
::';'
Kimbro, 1987; Nishida et al., 1988; Dresler & Frattini,
ft'
1988; Dresler et al., 1988). Selective inhibitors of pol 
Jf' such as COMDP might prove to be important tools in
experiments designed to define more precisely the role of
,-:
pol S in DNA repair.
:Wj
:1t
"&.
Inhibi tor studies: One ste toward definin the role of
DNA erase delta in DNA re lication. In conclusion, I
shall point out that several avenues must be pursued in
order to establish the function of pol When , in addition
to inhibitor studies, the gene for mammalian pol S is cloned
. .
and its relationship to that of pol a defined, when the
0" .
; :
expression of the pol 5 gene as a function of the cell cycle
is determined, and when cells carrying a conditionally
1 M. Frattini , University of Chicago, personal communication.
~~~..,
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mutant pol 5 gene are found and some deficiency in the
cells' DNA replication under nonpermissive conditions is
J;,
found, a strong statement on the role of pol 5 in mammalian
cell DNA replication will be possible.
., 
';4"
)';'
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